

Guidelines on **Renal Cell Carcinoma**

B. Ljungberg (chair), K. Bensalah, A. Bex, S. Canfield,
S. Dabestani, F. Hofmann, M. Hora, M.A. Kuczyk, T. Lam,
L. Marconi, A.S. Merseburger, P.F.A. Mulders, M. Staehler,
A. Volpe

TABLE OF CONTENTS

PAGE

1.	METHODOLOGY	5
1.1	Introduction	5
1.2	Methodology	5
1.2.1	Data identification	5
1.3	Level of evidence and grade of recommendation	6
1.4	Publication history	7
1.5	Future goals	7
1.6	Potential conflict of interest statement	7
1.5	References	7
2.	EPIDEMIOLOGY AND ETIOLOGY	8
2.1	Conclusion	8
2.2	Recommendation	8
2.3	References	8
3.	DIAGNOSIS AND STAGING	9
3.1	Symptoms	9
3.1.1	Physical examination	10
3.1.2	Laboratory findings	10
3.2	Imaging investigations	10
3.2.1	Presence of enhancement	10
3.2.2	CT or MRI	10
3.2.3	Other investigations	11
3.2.4	Radiographic investigations for metastatic RCC	11
3.2.5	Bosniak classification of renal cystic masses	11
3.3	Renal tumour biopsy (42-111)	12
3.4	Histological diagnosis	13
3.5	Conclusions	14
3.6	Recommendations	14
3.7	References	14
4.	CLASSIFICATION AND PROGNOSTIC FACTORS	20
4.1	Classification	20
4.2	Prognostic factors	21
4.2.1	Anatomical factors	21
4.2.2	Histological factors	22
4.2.4	Molecular factors	22
4.2.5	Prognostic systems and nomograms	22
4.3	Conclusions	22
4.4	Recommendations	23
4.5	References	25
5.	OTHER RENAL TUMOURS	27
5.1	Bellini duct carcinoma (collecting-duct carcinoma)	27
5.2	Renal medullary carcinoma	27
5.3	Sarcomatoid RCC	27
5.4	Unclassified RCC	28
5.5	Multilocular cystic RCC (cRCC)	28
5.6	Papillary adenoma	28
5.7	Translocation carcinoma (MITF/TFE family translocation-associated carcinoma)	28
5.8	Mucinous tubular and spindle cell carcinoma	28
5.9	Carcinoma associated with end-stage renal disease	28
5.10	Metanephric tumours	28
5.11	Renal epithelial and stromal tumours	29
5.12	Oncocytoma	29
5.13	Hereditary kidney tumours	29
5.14	Mesenchymal tumours	29
5.14.1	Angiomyolipoma	29

5.15	New histological entities	29
5.16	Summary	30
5.17	Recommendations	31
5.18	References	31
6.	TREATMENT OF LOCALISED RCC	34
6.1	Nephron-sparing surgery (partial tumour resection)	34
6.1.1	Associated procedures	34
6.1.1.1	Adrenalectomy	34
6.1.1.2	Lymph node dissection	34
6.1.1.3	Embolisation	34
6.1.1.4	Conclusions	35
6.1.1.5	Recommendations	35
6.1.2	Indications for nephron-sparing surgery	35
6.1.3	Complications	35
6.1.4	Prognosis	35
6.1.5	Conclusions	35
6.1.6	Recommendations	36
6.2	Laparoscopic surgery	36
6.2.1	Laparoscopic radical nephrectomy	36
6.2.1.1	Conclusions	36
6.2.1.2	Recommendations	36
6.2.2	Partial laparoscopic nephrectomy	36
6.2.2.1	Robotic-assisted partial nephrectomy	36
6.2.2.2	Conclusion	36
6.2.3	Recommendations	37
6.3	Therapeutic approaches as alternative to surgery	37
6.3.1	Surveillance	37
6.3.2	Percutaneous approaches	37
6.3.2.1	Radiofrequency ablation and cryoablation	37
6.3.2.2	Conclusions	37
6.3.2.3	Recommendations	38
6.4	Adjuvant therapy	38
6.4.1	Conclusion	38
6.4.2	Recommendation	38
6.5	Surgical treatment of metastatic RCC (tumour nephrectomy)	38
6.5.1	Conclusion	38
6.5.2	Recommendation	38
6.6	Resection of metastases	38
6.6.1	Conclusion	38
6.6.2	Recommendation	39
6.7	Radiotherapy for metastases in RCC	39
6.7.1	Conclusion	39
6.7.2	Recommendation	39
6.8	References	39
7.	SYSTEMIC THERAPY FOR METASTATIC RCC	45
7.1	Chemotherapy	45
7.1.1	Conclusion and recommendation	45
7.2	Immunotherapy	45
7.2.1	Interferon alpha as monotherapy and combined with bevacizumab	45
7.2.2	Interleukin-2	46
7.2.3	Vaccines and targeted immunotherapy	46
7.2.4	Conclusions	46
7.2.5	Recommendations	46
7.3	Drugs targeting VEGF, including other receptor kinases and mammalian target of rapamycin (mTOR)	46
7.3.1	Tyrosine kinase inhibitors	47
7.3.1.1	Sorafenib	47
7.3.1.2	Sunitinib	47

7.3.1.3	Pazopanib	48
7.3.1.4	Axitinib	48
7.3.1.5	Tivozanib	48
7.3.2	Monoclonal antibody against circulating VEGF	49
7.3.2.1	Bevacizumab monotherapy and combined with interferon alpha	49
7.3.3	Mammalian target of rapamycin (mTOR) inhibitors	49
7.3.3.1	Temsirolimus	49
7.3.3.2	Everolimus	49
7.3.4	Sequencing targeted therapy	49
7.3.5	Combination of targeted agents	49
7.3.6	Non-clear cell renal cancer	50
7.3.7	Conclusions	51
7.3.7	Recommendations for systemic therapy for mRCC	51
7.4	References	51
8.	FOLLOW-UP AFTER RADICAL OR PARTIAL NEPHRECTOMY OR ABLATIVE THERAPIES FOR RCC	54
8.1	Introduction	54
8.2	Which investigations for which patients, and when?	54
8.3	Conclusions and recommendations for surveillance following radical or partial nephrectomy or ablative therapies for RCC	55
8.4	References	55
9.	ABBREVIATIONS USED IN THE TEXT	58

1. METHODOLOGY

1.1 Introduction

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management of renal cell cancer. The RCC panel is an international group consisting of 10 clinicians with particular expertise in this field of urological care.

The guideline update methodology is detailed below, but for a substantial portion of the text the evidence base has been upgraded. The aim is to progress this further in the years to come.

Without the inspiration and practical assistance provided by Prof. James N'Dow, this would have been unattainable. We owe him and his UCAN team (Urological Cancer Charity, Scotland) a debt of gratitude. In the course of 2012, Dr. Thomas Lam joined our efforts and his support of the review team at his home institution (Aberdeen University Hospital), and in particular of the three young urologists who joined the RCC panel last year (Dr. Saeed Dabestani, Dr. Fabian Hofmann and Dr. Lorenzo Marconi), has been invaluable. Drs. Dabestani, Hofmann and Marconi have taken on the data management of the systematic reviews underpinning this 2013 publication.

For this 2013 update, the Panel did not manage to complete all systematic reviews in a timely fashion. As a result, sections of the document have been updated following a structured literature assessment. The focus for 2014 is to proceed with the systematic review, aiming for the complete guidelines document to be based on a uniformly high level of data work-up.

1.2 Methodology

1.2.1 Data identification

All chapters of the 2013 RCC Guidelines publication have been updated. As mentioned above, the consistency of the data work-up will differ between sections. An overview is presented in Table 1.

Table 1: Description of update and summary of review methodology

Chapter	Brief description of review methodology
Introduction	Not applicable
Epidemiology and etiology	The chapter has been updated using a structured data assessment
Diagnosis and staging	The chapter has been updated using a systematic review on tumour biopsy and a traditional narrative review for the other aspects of diagnosis and staging
Classification and prognostic factors	The chapter has been updated using a structured data assessment
Other renal tumors	The chapter has been updated using a traditional narrative review
Treatment of localised disease	The chapter has been updated using a systematic review
Systemic therapy for metastatic disease	The chapter has been updated using a mixed methods approach. Literature searching, study identification and data abstraction were carried out using systematic review methodology, with 54 studies being deemed eligible for inclusion. Ten of the most important and influential studies, as determined by consensus, were data-abstracted and the review was based on these 10 studies
Surveillance following radical or partial nephrectomy or ablative therapies	The chapter has been updated using a traditional narrative review

For the parts of the guideline that have been updated by way of a systematic review, the review methodology is outlined in detail elsewhere (1). In brief, a systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (2). Important topics and questions were prioritised by the panel for the present update. Elements for inclusion and exclusion, including patient population, intervention, comparison, outcomes, study design, and search terms and restrictions were developed using an iterative process involving all members of the panel, to achieve consensus. Individual literature searches were conducted separately for each update question, and in most instances the search was conducted up to the end of September 2012. Two independent reviewers screened abstracts and full texts, carried out data abstraction and assessed risk of bias. The results were presented in

tables showing baseline characteristics and summaries of findings. A narrative synthesis of the evidence was produced.

The remaining parts of the guideline have been updated using a traditional narrative review strategy. Structured literature searches using an expert consultant were designed. Searches were carried out in the Cochrane Database of Systematic Reviews, the Cochrane Library of Controlled Clinical Trials and Medline and Embase on the Dialog-Datatar platform. The controlled terminology of the respective databases was used, and both MesH and Emtree were analysed for relevant entry terms. The search strategies covered the last 3 years. An update search was carried out before the publication of this document. Other data sources were also consulted, such as the Database of Abstracts of Reviews of Effectiveness (DARE), as well as relevant reference lists from other guidelines producers such as the National Institute for Clinical Excellence (NICE) and the American Urological Association (AUA).

Most reviewed studies are retrospective analyses that include some larger multicentre studies and well-designed controlled studies. As only a few randomised controlled trials are available, there is a certain lack of data with a strong evidence base. Conversely, in the systemic treatment of metastasised RCC, a number of randomised studies have been performed, resulting in highly evidence-based recommendations.

1.3 Level of evidence and grade of recommendation

References in the text have been assessed according to their level of scientific evidence (Table 1), and guideline recommendations have been graded (Table 3) according to the Oxford Centre for Evidence-based Medicine Levels of Evidence (3). Grading aims to provide transparency between the underlying evidence and the recommendation given.

Table 2: Level of evidence*

Level	Type of evidence
1a	Evidence obtained from meta-analysis of randomised trials.
1b	Evidence obtained from at least one randomised trial.
2a	Evidence obtained from one well-designed controlled study without randomisation.
2b	Evidence obtained from at least one other type of well-designed quasi-experimental study.
3	Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4	Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

* Adapted from (3).

It should be noted that when recommendations are graded, the link between the level of evidence (LE) and the grade of recommendation (GR) is not directly linear. The availability of randomised controlled trials (RCTs) may not necessarily translate into a grade A recommendation when there are methodological limitations or disparities in the published results.

Conversely, an absence of a high level of evidence does not necessarily preclude a grade A recommendation if there is overwhelming clinical experience and consensus. There may be exceptional situations in which corroborating studies cannot be performed, perhaps for ethical or other reasons, and in this case unequivocal recommendations are considered helpful. Whenever this occurs, it is indicated in the text as “upgraded based on panel consensus.” The quality of the underlying scientific evidence - although a very important factor - has to be balanced against benefits and burdens, values and preferences, and costs when a grade is assigned (4-6).

The EAU Guidelines Office does not perform structured cost assessments, nor can it address local/national preferences in a systematic fashion. But whenever these data are available, the expert panel will include the information.

Table 3: Grade of recommendation*

Grade	Nature of recommendations
A	Based on clinical studies of good quality and consistency that addressed the specific recommendations, including at least one randomised trial.
B	Based on well-conducted clinical studies, but without randomised clinical trials.
C	Made despite the absence of directly applicable clinical studies of good quality.

* Adapted from (3).

1.4 Publication history

The EAU Renal Cell Cancer Guidelines were first published in 2000, with subsequent updates in 2001 (limited update), 2002 (limited update), and 2006 (full update), and partial updates in 2007, 2008, 2009, and 2010. This current 2013 printing presents a full-text update.

A quick reference guide presenting the main findings of the Renal Cell Cancer Guidelines is also available (Pocket Guidelines), as well as a number of scientific publications in the EAU journal, European Urology (7-9). All of the texts can be viewed and downloaded for personal use at the society's web site: <http://www.uroweb.org/guidelines/online-guidelines/>.

The RCC panel recognises that there is a constant need to reevaluate the published evidence for this particular topic, but the next update, scheduled for 2014, will focus on covering sections with systematic reviews that could not be completed for the current printing.

1.5 Future goals

In addition to the systematic review, a number of other goals need to be taken into account. These include patient-derived needs, as well as recommendations requested by the ordinary urologist. We will be introducing such thoughts in the coming updates.

1.6 Potential conflict of interest statement

The members of the expert panel have submitted potential conflict of interest statements, which can be viewed on the EAU web site: <http://www.uroweb.org/guidelines/>.

1.5 References

- Dabestani S, Hofmann F, Marconi L, et al. EAU Renal Cell Cancer Guideline Panel. Systematic review methodology for the EAU RCC Guideline update 2013. http://www.uroweb.org/gls/refs/Systematic_methodology_RCC_2013_update.pdf
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009 Oct;62(10):1006-12. [no abstract available] <http://www.ncbi.nlm.nih.gov/pubmed/19631508>
- Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Produced by Updated by Jeremy Howick March 2009. <http://www.cebm.net/index.aspx?o=1025> [Access date February 2013]
- Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004 Jun 19;328(7454):1490. <http://www.ncbi.nlm.nih.gov/pubmed/15205295>
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 Apr;336(7650):924-6. <http://www.ncbi.nlm.nih.gov/pubmed/18436948>
- Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. BMJ 2008 May 10;336(7652):1049-51. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376019/?tool=pubmed>
- Mickish G, Carballido J, Hellsten S, et al. EAU Guidelines on Renal Cell Cancer. Eur Urol 2001 Sep; 40(3):252-55. <http://www.ncbi.nlm.nih.gov/pubmed/11684839>
- Ljungberg B, Hanbury DC, Kuczyk M, et al. EAU Renal Cell Carcinoma Guidelines. Eur Urol 2007 Jun;51(6):1502-10. <http://www.ncbi.nlm.nih.gov/pubmed/17408850>

9. Ljungberg B, Cowan C., Hanbury DC, et al. EAU Guidelines on Renal Cell Carcinoma; The 2010 Update. *Eur Urol* 2010 Sep;58(3):398-406.
<http://www.ncbi.nlm.nih.gov/pubmed/20633979>

2. EPIDEMIOLOGY AND ETIOLOGY

Renal cell carcinoma (RCC) represents 2-3% of all cancers with an age-standardised rate incidence of 5.8 and mortality of 1.4 per 100,000, respectively, in more developed areas (1). The highest incidence all over the world is in the Czech Republic, where in 2010 the incidence rate was 14.62 and mortality 5.17 (age-standardised rate/world per 100,000) (2).

Generally, during the last two decades and until recently, there has been an annual increase of about 2% in the incidence both worldwide and in Europe, although in Denmark and Sweden a continuing decrease has been observed (3). In 2008, it was estimated that there were 88,400 new cases of RCC and 39,300 kidney cancer-related deaths in the European Union (4). In Europe, the overall mortality rates for RCC increased up until the early 1990s, with rates generally stabilising in the following years, but increasing again in recent years (5). There has been a decrease in the mortality since the 1980s in Scandinavian countries and since the early 1990s in France, Germany, Austria, the Netherlands, and Italy. However, in some European countries (Croatia, Estonia, Greece, Ireland, Slovakia), the mortality rates are still showing an upward trend, with increasing rates (5). The mortality rate in Europe is 14,500 in females and 24,800 in males (both sexes 39,300) (4).

Renal cell carcinoma is the commonest solid lesion in the kidney and accounts for approximately 90% of all kidney malignancies. It includes different types, with specific histopathological and genetic characteristics (6). There is a 1.5:1.0 predominance of men over women, with the peak incidence occurring between the ages of 60 and 70. Etiological factors include lifestyle factors such as smoking, obesity, and hypertension (7-11). Obesity is a controversial issue, as there have been reports showing a better prognosis for obese patients suffering from renal cell cancer (12). Having a first-degree relative with kidney cancer is also associated with an increased risk of RCC (13,14). The most effective prophylaxis is to avoid cigarette smoking and obesity.

As tumours are detected more frequently using imaging techniques such as ultrasound and computed tomography (CT), the numbers of RCCs diagnosed incidentally has increased. These tumours are more often smaller and at a lower stage (15-17).

2.1 Conclusion

Several verified risk factors have been identified, including smoking, obesity, and hypertension. Cigarette smoking is a definite risk factor for RCC (LE: 2a).

2.2 Recommendation

	GR
The most important methods for primary prevention of RCC are to eliminate cigarette smoking and avoid obesity.	B

2.3 References

- Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin*. 2011 Mar-Apr;61(2):69-90.
<http://www.ncbi.nlm.nih.gov/pubmed/21296855>
- Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 2010 Mar;46(4):765-81.
<http://www.ncbi.nlm.nih.gov/pubmed/20116997>
- Lindblad P. Epidemiology of renal cell carcinoma. *Scand J Surg* 2004;93(2):88-96.
<http://www.ncbi.nlm.nih.gov/pubmed/15285559>
- Ferlay J, S.H., Bray F, Forman D, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer: Lyon, France.
<http://www.iarc.fr/en/publications/eresources/cancerbases/index.php>
- Levi F, Ferlay J, Galeone C, et al. The changing pattern of kidney cancer incidence and mortality in Europe. *BJU Int* 2008 Apr;101(8):949-58.
<http://www.ncbi.nlm.nih.gov/pubmed/18241251>

6. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. *J Pathol* 1997 Oct;183(2):131-3.
<http://www.ncbi.nlm.nih.gov/pubmed/9390023>
7. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. *J Urol* 2006; Dec;176(6 Pt 1):2353-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17085101>
8. International Agency for Research on cancer (IARC). WHO IARC monographs. Vol. 83, 2004. Available at: <http://monographs.iarc.fr/ENG/Monographs/vol83/index.php> [Accessed January 2012].
9. Bergstrom A, Hsieh CC, Lindblad P, et al. Obesity and renal cell cancer-a quantitative review. *Br J Cancer* 2001 Sep;85(7):984-90.
<http://www.ncbi.nlm.nih.gov/pubmed/11592770>
10. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2006 Feb;118(3):728-38.
<http://www.ncbi.nlm.nih.gov/pubmed/16094628>
11. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. *Am J Epidemiol* 2008 Feb;167(4):438-46.
<http://www.ncbi.nlm.nih.gov/pubmed/18048375>
12. Waalkes S, Merseburger AS, Kramer MW, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. *Cancer Causes Control* 2010 Nov;21(11):1905-10.
13. Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case control study and systematic meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2009 Mar;18(3):801-7.
<http://www.ncbi.nlm.nih.gov/pubmed/19240244>
14. Gudbjartsson T, Jónasdóttir TJ, Thoroddsen A, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. *Int J Cancer* 2002 Aug;100(4):476-9.
<http://www.ncbi.nlm.nih.gov/pubmed/12115533>
15. Patard JJ, Rodriguez A, Rioux-Leclercq N, et al. Prognostic significance of the mode of detection in renal tumours. *BJU Int* 2002 Sep;90(4):358-63.
<http://www.ncbi.nlm.nih.gov/pubmed/12175389>
16. Kato M, Suzuki T, Suzuki Y, et al. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. *J Urol* 2004 Sep;172(3):863-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15310984>
17. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. *J Urol* 2000 Feb;163(2):426-30.
<http://www.ncbi.nlm.nih.gov/pubmed/10647646>

3. DIAGNOSIS AND STAGING

3.1 Symptoms

Many renal masses remain asymptomatic until the late stages of the disease. Currently, more than 50% of RCCs are detected incidentally when non-invasive imaging is used to investigate a variety of nonspecific symptoms and other abdominal diseases (1,2) (LE: 3). The classic triad of flank pain, gross hematuria, and palpable abdominal mass is now rare (6-10%) and correlates with aggressive histology and advanced disease (3,4) (LE: 3). Paraneoplastic syndromes are found in approximately 30% of patients with symptomatic RCCs (Table 4) (LE: 4). A few symptomatic patients present with symptoms caused by metastatic disease, such as bone pain or persistent cough (5) (LE: 3).

Table 4. Most common paraneoplastic syndromes

- Hypertension
- Cachexia
- Weight loss
- Pyrexia
- Neuromyopathy
- Amyloidosis
- Elevated erythrocyte sedimentation rate
- Anemia
- Abnormal liver function
- Hypercalcemia
- Polycythemia

3.1.1 **Physical examination**

Physical examination has only a limited role in the diagnosis of RCC. However, the following findings should prompt radiological examinations:

- Palpable abdominal mass;
- Palpable cervical lymphadenopathy;
- Nonreducing varicocele and bilateral lower extremity edema, that suggests venous involvement.

3.1.2 **Laboratory findings**

The most commonly assessed laboratory parameters are serum creatinine, glomerular filtration rate (GFR), complete cell blood count, erythrocyte sedimentation rate, liver function study, alkaline phosphatase, lactate dehydrogenase (LDH), serum corrected calcium (6,7), coagulation study, and urinalysis (LE: 4).

If there are central renal masses abutting or invading the collecting system, urinary cytology and possibly endoscopic assessment of the upper urinary tract should be considered in order to rule out the presence of urothelial cancer (LE: 4).

Split renal function should be estimated using renal scintigraphy in the following situations (8,9) (LE: 2b):

- When renal function is compromised, as indicated by an increased concentration of serum creatinine or a significantly decreased GFR.
- When renal function is clinically important - e.g., in patients with a solitary kidney or multiple or bilateral tumours (as in the hereditary forms of RCC).

Renal scintigraphy is an additional diagnostic option in patients who are at risk of future renal impairment due to comorbid disorders - e.g., diabetes, severe hypertension, chronic pyelonephritis, renovascular disease, urinary stones, or renal polycystic disease.

3.2 **Imaging investigations**

Most renal tumours are diagnosed when abdominal ultrasonography (US) or computed tomography (CT) are carried out for other medical reasons (LE: 3) (1).

Renal masses can be classified as solid or cystic on the basis of the imaging findings.

3.2.1 **Presence of enhancement**

With solid renal masses, the most important criterion for differentiating malignant lesions is the presence of enhancement (10) (LE: 3). The traditional approach for detecting and characterising renal masses is to use US, CT, or magnetic resonance imaging (MRI). Most renal masses can be diagnosed accurately using imaging alone. Contrast-enhanced US can be helpful in specific cases (e.g., chronic renal failure with a relative contraindication for iodinated or gadolinium contrast media, complex cystic masses, and differential diagnosis of peripheral vascular disorders such as infarction and cortical necrosis) (11-13) (LE: 3).

3.2.2 **CT or MRI**

Computed tomography or MRI are used to characterise a renal mass. Imaging must be performed both before and after administration of intravenous contrast material in order to demonstrate enhancement. In CT imaging, enhancement in renal masses is determined by comparing Hounsfield unit (HU) readings before and after contrast administration. A change of 15 Hounsfield units or more is evidence of enhancement (14) (LE: 3). To maximise differential diagnosis and detection, the evaluation should include images from the nephrographic phase, as this phase provides the best depiction of renal masses, which typically do not enhance to the same degree as the renal parenchyma.

CT or MRI allow accurate diagnosis of RCC in most cases. However, CT and MRI features cannot reliably distinguish oncocytoma and fat-free angiomyolipoma from malignant renal neoplasms (15-18) (LE: 3).

Abdominal CT provides information on:

- Function and morphology of the contralateral kidney (19) (LE: 3);
- Primary tumour extension (extrarenal spread);
- Venous involvement;
- Enlargement of locoregional lymph nodes;
- Condition of the adrenal glands and liver (LE: 3).

Abdominal contrast-enhanced biphasic CT angiography is a useful tool in selected cases to obtain detailed information about the renal vascular supply (e.g., for segmental renal artery clamping during partial nephrectomy) (20,21). If the patient is allergic to CT contrast medium, MRI biphasic angiography (MRA) may be indicated, but this is less sensitive and accurate than CT angiography for detecting supernumerary vessels (22). If the results of CT are indeterminate, MRI may provide additional information in order to:

- Demonstrate enhancement in renal masses (including solid enhancing nodular components in complex cystic masses) (23);
- Investigate locally advanced malignancy (24-26);
- Investigate venous involvement if the extent of an inferior vena cava tumour thrombus is poorly defined on CT scanning (24-27) (LE: 3). Doppler US is less accurate for identification of the extent of a venous tumour thrombus (26) (LE: 3).

MRI is indicated in patients who are allergic to intravenous CT contrast medium and in pregnancy without renal failure (25,28) (LE: 3). Advanced MRI techniques such as diffusion-weighted and perfusion-weighted imaging are being explored in the assessment of renal masses (29).

3.2.3 **Other investigations**

Renal arteriography and inferior venacavography only have a limited role in the work-up of selected patients with RCC (LE: 3). In patients with any sign of impaired renal function, an isotope renogram and total renal function evaluation should be considered in order to optimise treatment decision-making - e.g., the need to preserve renal function (8,9) (LE: 2a).

The true value of positron-emission tomography (PET) in the diagnosis and follow-up of RCC remains to be determined, and PET is not currently a standard investigation (30) (LE: 3).

3.2.4 **Radiographic investigations for metastatic RCC**

Chest CT is the most accurate investigation for chest staging (31-35) (LE: 3). However, at the very least, routine chest radiography must be performed for metastatic evaluation, as a less accurate alternative to chest CT (LE: 3). There is a consensus that most bone and brain metastases are symptomatic at diagnosis, so that routine bone or brain imaging is not generally indicated (31,36,37) (LE: 3). However, bone scan, brain CT, or MRI may be used in presence of specific clinical or laboratory signs and symptoms (37-39) (LE: 3).

3.2.5 **Bosniak classification of renal cystic masses**

For the evaluation of renal cystic masses, the Bosniak classification classifies renal cysts into five categories based on their CT imaging appearance, in an attempt to predict the risk of malignancy (40,41) (LE: 3). The Bosniak system also advocates treatment for each category (Table 4).

Table 4: The Bosniak classification of renal cysts (40)

Bosniak category	Features	Work-up
I	A simple benign cyst with a hairline-thin wall that does not contain septa, calcification, or solid components. It has the same density as water and does not enhance with contrast medium.	Benign
II	A benign cyst that may contain a few hairline-thin septa. Fine calcification may be present in the wall or septa. Uniformly high-attenuation lesions < 3 cm in size, with sharp margins but without enhancement.	Benign
IIF	These cysts may contain more hairline-thin septa. Minimal enhancement of a hairline-thin septum or wall can be seen. There may be minimal thickening of the septa or wall. The cyst may contain calcification, which may be nodular and thick, but there is no contrast enhancement. There are no enhancing soft-tissue elements. This category also includes totally intrarenal, non-enhancing, high-attenuation renal lesions ≥ 3 cm in size. These lesions are generally well-marginated.	Follow-up. A small proportion are malignant
III	These lesions are indeterminate cystic masses that have thickened irregular walls or septa in which enhancement can be seen.	Surgery or follow-up. Over 50% of the lesions are malignant
IV	These lesions are clearly malignant cystic lesions that contain enhancing soft-tissue components.	Surgical therapy recommended. Mostly malignant tumour

3.3 Renal tumour biopsy (42-111)

Percutaneous renal tumour biopsies are increasingly being used: 1, for histological diagnosis of radiologically indeterminate renal masses; 2, to select patients with small renal masses for surveillance approaches; 3, to obtain histology before ablative treatments; 4, to select the most suitable form of targeted pharmacologic therapy in the setting of metastatic disease (42-51) (LE: 3).

Percutaneous sampling of a renal mass can be carried out using needle core biopsy and/or fine-needle aspiration (FNA). The aim is to determine malignancy, histological type, and grade of the renal tumour evaluated.

Due to the high diagnostic accuracy of current abdominal imaging findings, renal tumour biopsy is not necessary before surgical treatment in fit patients with a long life expectancy and a clearly suspicious, contrast-enhancing renal mass at abdominal CT or MRI (LE: 4).

Percutaneous sampling of renal masses can be performed under local anesthesia in the majority of cases (42-51) (LE: 3). Depending on the tumour's location, its echogenic features, and the patient's physical characteristics, biopsies can be performed with either ultrasound or CT guidance, with a similar diagnostic yield (47,50) (LE: 2b).

There is currently agreement that 18-gauge needles are ideal for renal tumour core biopsies, as they are associated with low morbidity and provide sufficient tissue for diagnosis in the majority of cases (42-50,52) (LE: 2b). A coaxial technique that allows multiple biopsies to be performed through a coaxial guide or cannula should always be used, in order to avoid the potential risk of tumour seeding (42-50) (LE: 3). With the use of coaxial techniques, no cases of seeding of renal tumours have been reported in recent years (42-50).

Overall, percutaneous biopsies have low morbidity. Spontaneously resolving subcapsular/perinephric hematoma and hematuria are the most frequently reported complications, while clinically significant bleeding is unusual (0-1.4%) and generally self-limiting (42-111).

Needle core biopsies are preferable for solid renal masses, as they have a greater diagnostic yield and better accuracy for diagnosing malignancy and histological type in comparison with FNA (44,47,49,53-55) (LE: 2b). Larger tumour size and solid pattern are predictors of a diagnostic core biopsy (47,50) (LE: 2b).

The ideal number and location of core biopsies have not been defined. However, at least two good-

quality cores (nonfragmented, > 10 mm in length) should be obtained, and necrotic areas should be avoided in order to maximize the diagnostic yield (42,44,47,48,50) (LE: 4). Peripheral biopsies are preferable for larger tumours, to avoid areas of central necrosis (56) (LE: 2b).

In recent series from experienced centers, core biopsies of solid renal tumours have shown a diagnostic yield of 78-97%, high specificity (98-100%), and high sensitivity (86-100%) for the diagnosis of malignancy (42-50,54,55,57-75) (LE: 2b). However, it should be noted that 2.5-22% of core biopsies are nondiagnostic (42-50,54,55,57-75) (LE: 2b). If a biopsy is nondiagnostic, but there are radiologic findings suspicious for malignancy, a further biopsy or surgical exploration should always be considered (LE: 4).

Assessment of tumour grade on core biopsies is challenging. The accuracy of Fuhrman grading on biopsies is poor (43-75%), but it can be improved using a simplified two-tier system (high-grade vs. low grade) (42-50,54,55,57-75) (LE: 2b).

Core biopsies have a low diagnostic yield for cystic renal masses and should not be recommended alone in these cases, unless areas with a solid pattern are present (Bosniak IV cysts) (47,50) (LE: 2b). Combined FNA and core biopsies can provide complementary results, especially for complex cystic lesions (49,55,57,58,73,76,77) (LE: 3).

3.4 Histological diagnosis

The histological diagnosis of RCC is established after surgical removal of renal tumours with radical or partial nephrectomy or after percutaneous biopsy.

According to the World Health Organization (112), there are three major histological subtypes of RCC:

- Clear cell (cRCC, 80-90%)
- Papillary (pRCC, 10-15%)
- Chromophobe (chRCC, 4-5%)

These RCC types can be differentiated on the basis of histological and genetic features (110) (LE: 3) (Table 5). Papillary RCC can be further divided into two different subtypes, type 1 and type 2 (Table 5) (113,114) (LE: 3).

Table 5: Major histological subtypes of RCC

Histological subtype	Percentage of RCC	Histological description	Associated genetic changes
Clear cell (cRCC)	80-90%	Most cRCC are composed predominantly of cells containing clear cytoplasm, although eosinophilic cytoplasm predominates in some cells. The growth pattern may be solid, tubular, and cystic.	Identified by the specific deletion of chromosome 3p and mutation of the VHL gene. Other changes are duplication of the chromosome band 5q22, deletion of chromosome 6q, 8p, 9p, and 14q.
Papillary (pRCC)	10-15%	Most pRCCs have small cells with scanty cytoplasm, but also basophilic, eosinophilic, or pail-staining characteristics. A papillary growth pattern predominates, although there may be tubular papillary and solid architectures. Necrotic areas are common. Papillary RCC can be divided into two different subtypes: type 1 with small cells and pale cytoplasm and type 2 with large cells and eosinophilic cytoplasm, the latter having a worse prognosis.	The most consistent genetic alterations are trisomies of chromosomes 3q, 7, 8, 12, 16, 17, and loss of the y chromosome.
Chromophobe (chRCC)	4-5%	The cells of chRCC may have pail or eosinophilic granular cytoplasm. Growth usually occurs in solid sheets.	The genetic characteristic is a combination of loss of chromosomes 1, 2, 6, 10, 13, and 17.

3.5 Conclusions

- The incidence of small and incidental renal tumours has significantly increased in recent decades, but a proportion of patients with RCC still present with a palpable mass, hematuria, and paraneoplastic

and metastatic symptoms (LE: 3). Appropriate staging of RCC requires abdominal CT or MRI and chest imaging (LE: 3). Chest CT is the most sensitive approach for detecting lung metastases, but at least a chest radiograph should be performed for chest staging. There is no role for routine bone scanning or brain CT or MRI in the standard clinical work-up of asymptomatic patients.

- Percutaneous renal tumour biopsies are increasingly being used: 1, to establish the diagnosis of radiologically indeterminate renal masses; 2, to obtain histology of incidentally detected renal masses in patients who are candidates for nonsurgical treatment (active surveillance, ablative therapies); and 3, to select the most suitable targeted therapy for metastatic renal tumours.

3.6 Recommendations

	GR
In a patient with one or more suspicious laboratory or physical findings, the possible presence of RCC should be suspected.	B
Contrast-enhanced abdominal CT and MRI are recommended for the work-up of patients with RCC. These are the most appropriate imaging modalities for renal tumour staging prior to surgery.	A
A chest CT is most sensitive for assessment of the lung, but at least a plain chest radiograph should be taken for clinical staging.	A
In patients at risk for bone metastases (raised alkaline phosphatase level or bone pain), further evaluation with a bone scan is needed.	A
Evaluation of renal function is recommended before treatment decision in any patient in whom renal impairment is suspected.	B
Percutaneous biopsy is always required before ablative therapy and systemic therapy without previous pathology.	A
Percutaneous biopsy is recommended in active surveillance strategies in order to stratify the follow-up according to tumour histology.	B
When biopsy is indicated, good-quality needle cores should be obtained with a coaxial technique in order to increase the safety of the procedure and maximise its diagnostic yield.	B

3.7 References

1. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. *Urology* 1998 Feb;51(2):203-5.
<http://www.ncbi.nlm.nih.gov/pubmed/9495698>
2. Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? *Eur Urol* 2010 Oct;58(4):588-95.
<http://www.ncbi.nlm.nih.gov/pubmed/20674150>
3. Lee CT, Katz J, Fearn PA, et al. Mode of presentation of renal cell carcinoma provides prognostic information. *Urol Oncol* 2002 Jul-Aug;7(4):135-40.
<http://www.ncbi.nlm.nih.gov/pubmed/12474528>
4. Patard JJ, Leray E, Rodriguez A, et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. *Eur Urol* 2003 Aug;44(2):226-32.
<http://www.ncbi.nlm.nih.gov/pubmed/12875943>
5. Kim HL, Belldegrin AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. *J Urol* 2003 Nov;170(5):1742-6.
<http://www.ncbi.nlm.nih.gov/pubmed/14532767>
6. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002 Jan 1;20(1):289-96.
<http://www.ncbi.nlm.nih.gov/pubmed/11773181>
7. Sufrin G, Chasan S, Golio A, et al. Paraneoplastic and serologic syndromes of renal adenocarcinoma. *Semin Urol* 1989 Aug;7(3):158-71.
<http://www.ncbi.nlm.nih.gov/pubmed/2690260>
8. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. *J Urol* 2001 Jul;66(1):6-18.
<http://www.ncbi.nlm.nih.gov/pubmed/11435813>
9. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol* 2006 Sep;7(9):735-40.
<http://www.ncbi.nlm.nih.gov/pubmed/16945768>

10. Israel GM, Bosniak MA. How I do it: evaluating renal masses. *Radiology* 2005 Aug;236(2):441-50.
<http://www.ncbi.nlm.nih.gov/pubmed/16040900>
11. Fan L, Lianfang D, Jinfang X, et al. Diagnostic efficacy of contrast-enhanced ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. *J Ultrasound Med* 2008 Jun;27(6):875-85.
<http://www.ncbi.nlm.nih.gov/pubmed/18499847>
12. Correas JM, Tranquart F, Claudon M. [Guidelines for contrast enhanced ultrasound (CEUS)-update 2008.] *J Radiol* 2009 Jan;90(1 Pt 2):123-38. [Article in French]
<http://www.ncbi.nlm.nih.gov/pubmed/19212280>
13. Mitterberger M, Pelzer A, Colleselli D, et al. Contrast-enhanced ultrasound for diagnosis of prostate cancer and kidney lesions. *Eur J Radiol* 2007 Nov;64(2):231-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17881175>
14. Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. *Radiographics* 2008 Sep-Oct;28(5):1325-38.
<http://www.ncbi.nlm.nih.gov/pubmed/18794310>
15. Choudhary S, Rajesh A, Mayer NJ, et al. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. *Clin Radiol* 2009 May;64(5):517-22.
<http://www.ncbi.nlm.nih.gov/pubmed/19348848>
16. Rosenkrantz AB, Hindman N, Fitzgerald EF, et al. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. *AJR Am J Roentgenol* 2010 Dec;195(6):W421-7.
<http://www.ncbi.nlm.nih.gov/pubmed/21098174>
17. Hindman N, Ngo L, Genega EM, et al. Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? *Radiology* 2012 Nov;265(2):468-77.
<http://www.ncbi.nlm.nih.gov/pubmed/23012463>
18. Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. *Radiographics* 2008 Jul-Aug;28(4):985-1003.
<http://www.ncbi.nlm.nih.gov/pubmed/18635625>
19. Gong IH, Hwang J, Choi DK, et al. Relationship among total kidney volume, renal function and age. *J Urol* 2012 Jan;187(1):344-9.
<http://www.ncbi.nlm.nih.gov/pubmed/22099987>
20. Ferda J, Hora M, Hes O, et al. Assessment of the kidney tumor vascular supply by two-phase MDCTangiography. *Eur J Radiol* 2007 May;62(2):295-301.
<http://www.ncbi.nlm.nih.gov/pubmed/17324548>
21. Shao P, Tang L, Li P, et al. Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. *Eur Urol* 2012 Dec;62(6):1001-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22695243>
22. Hora M, Stránský P, Trávníček I, et al. Three-tesla MRI biphasic angiography: a method for preoperative assessment of the vascular supply in renal tumours-a surgical perspective. *World J Urol*. 2012 Apr 19. [Epub ahead of print]
<http://www.ncbi.nlm.nih.gov/pubmed/22527675>
23. Adey GS, Pedrosa I, Rofsky NM, et al. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. *Urology* 2008 Jan;71(1):47-51.
<http://www.ncbi.nlm.nih.gov/pubmed/18242363>
24. Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. *Crit Rev Diagn Imaging* 1991;32(2):69-118.
<http://www.ncbi.nlm.nih.gov/pubmed/1863349>
25. Krestin GP, Gross-Fengels W, Marincek B. [The importance of magnetic resonance tomography in the diagnosis and staging of renal cell carcinoma.] *Radiologe* 1992;32(3):121-6. [Article in German]
<http://www.ncbi.nlm.nih.gov/pubmed/1565792>
26. Mueller-Lisse UG, Mueller-Lisse UL. Imaging of advanced renal cell carcinoma. *World J Urol* 2010 Jun;28(3):253-61.
<http://www.ncbi.nlm.nih.gov/pubmed/20458484>
27. Kabala JE, Gillatt DA, Persad RA, et al. Magnetic resonance imaging in the staging of renal cell carcinoma. *Br J Radiol* 1991;64(764):683-9.
<http://www.ncbi.nlm.nih.gov/pubmed/1884119>
28. Putra LG, Minor TX, Bolton DM, et al. Improved assessment of renal lesions in pregnancy with magnetic resonance imaging. *Urology* 2009 Sep;74(3):535-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19604560>

29. Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. *Eur Urol* 2012 Feb;61(2):326-40.
<http://www.ncbi.nlm.nih.gov/pubmed/22000497>
30. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. *BJU Int* 2009 Mar;103(5):615-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19007371>
31. Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. *Urol Clin North Am* 1997;24(3):507-22.
<http://www.ncbi.nlm.nih.gov/pubmed/9275976>
32. Heidenreich A, Ravary V. European Society of Oncological Urology. Preoperative imaging in renal cell cancer. *World J Urol* 2004;22(5):307-15.
<http://www.ncbi.nlm.nih.gov/pubmed/15290202>
33. Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. *Radiographics* 2001;21 Spec No:S237-54.
<http://www.ncbi.nlm.nih.gov/pubmed/11598260>
34. Miles KA, London NJ, Lavelle JM, et al. CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques. *Eur J Radiol* 1991;13(1):37-42.
<http://www.ncbi.nlm.nih.gov/pubmed/1889427>
35. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. *J Urol* 1993;150(4):1112-4.
<http://www.ncbi.nlm.nih.gov/pubmed/8371366>
36. Koga S, Tsuda S, Nishikido M, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. *J Urol* 2001 Dec;166(6):2126-8.
<http://www.ncbi.nlm.nih.gov/pubmed/11696720>
37. Marshall ME, Pearson T, Simpson W, et al. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. *Urology* 1990 Oct;36(4):300-2.
<http://www.ncbi.nlm.nih.gov/pubmed/2219605>
38. Henriksson C, Haraldsson G, Aldenborg F, et al. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. *Scand J Urol Nephrol* 1992;26(4):363-6.
<http://www.ncbi.nlm.nih.gov/pubmed/1292074>
39. Seaman E, Goluboff ET, Ross S, et al. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. *Urol* 1996;48(5):692-5.
<http://www.ncbi.nlm.nih.gov/pubmed/8911510>
40. Warren KS, McFarlane J. The Bosniak classification of renal cystic masses. *BJU Int* 2005 May;95(7):939-42.
<http://www.ncbi.nlm.nih.gov/pubmed/15839908>
41. Bosniak MA. The use of the Bosniak classification system for renal cysts and cystic tumors. *J Urol* 1997 May;157(5):1852-3.
<http://www.ncbi.nlm.nih.gov/pubmed/9112545>
42. Neuzillet Y, Lechevallier E, Andre M, et al. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. *J Urol* 2004 May;171(5):1802-5.
<http://www.ncbi.nlm.nih.gov/pubmed/15076280>
43. Shannon BA, Cohen RJ, de Bruto H, et al. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. *J Urol* 2008 Oct;180(4):1257-61; discussion 1261.
<http://www.ncbi.nlm.nih.gov/pubmed/18707712>
44. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. *Eur Urol* 2008 May;53(5):1003-11.
<http://www.ncbi.nlm.nih.gov/pubmed/18061339>
45. Leuret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. *J Urol* 2007 Oct;178(4 Pt 1):1184-8; discussion 1188.
<http://www.ncbi.nlm.nih.gov/pubmed/17698122>
46. Maturen KE, Nghiem HV, Caoili EM, et al. Renal mass core biopsy: accuracy and impact on clinical management. *AJR Am J Roentgenol* 2007 Feb;188(2):563-70.
<http://www.ncbi.nlm.nih.gov/pubmed/17242269>

47. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. *J Urol* 2008 Dec;180(6):2333-7.
<http://www.ncbi.nlm.nih.gov/pubmed/18930274>
48. Wang R, Wolf JS Jr, Wood DP Jr, et al. Accuracy of percutaneous core biopsy in management of small renal masses. *Urology* 2009 Mar;73(3):586-90; discussion 590-1.
<http://www.ncbi.nlm.nih.gov/pubmed/19118884>
49. Veltri A, Garetto I, Tosetti I, et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. *Eur Radiol* 2011 Feb;21(2):393-401.
<http://www.ncbi.nlm.nih.gov/pubmed/20809129>
50. Leveridge MJ, Finelli A, Kachura JR, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. *Eur Urol* 2011 Sep;60(3):578-84.
<http://www.ncbi.nlm.nih.gov/pubmed/21704449>
51. Abel EJ, Culp SH, Matin SF, et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. *J Urol* 2010 Nov;184(5):1877-81.
<http://www.ncbi.nlm.nih.gov/pubmed/20850148>
52. Breda A, Treat EG, Haft-Candell L, et al. Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. *BJU Int* 2010 Apr;105(7):940-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19888984>
53. Aribas BK, Arda K, Aktas E, et al. Percutaneous US-guided needle biopsies of solid renal masses. *Neoplasma* 2011;58(2):146-52.
<http://www.ncbi.nlm.nih.gov/pubmed/21275465>
54. Beland MD, Mayo-Smith WW, Dupuy DE, et al. Diagnostic yield of 58 consecutive imaging-guided biopsies of solid renal masses: should we biopsy all that are indeterminate? *AJR Am J Roentgenol* 2007 Mar;188(3):792-7.
<http://www.ncbi.nlm.nih.gov/pubmed/17312070>
55. Li G, Cuilleron M, Zhao A, et al. Combination of core biopsy and fine-needle aspiration increases diagnostic rate for small solid renal tumors. *Anticancer Res* 2012 Aug;32(8):3463-6.
<http://www.ncbi.nlm.nih.gov/pubmed/22843931>
56. Wunderlich H, Hindermann W, Al Mustafa AM, et al. The accuracy of 250 fine needle biopsies of renal tumors. *J Urol* 2005 Jul;174(1):44-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15947574>
57. Parks GE, Perkins LA, Zagoria RJ, et al. Benefits of a combined approach to sampling of renal neoplasms as demonstrated in a series of 351 cases. *Am J Surg Pathol* 2011 Jun;35(6):827-35.
<http://www.ncbi.nlm.nih.gov/pubmed/21552112>
58. Wood BJ, Khan MA, McGovern F, et al. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. *J Urol* 1999 May;161(5):1470-4.
<http://www.ncbi.nlm.nih.gov/pubmed/10210375>
59. Blumenfeld AJ, Guru K, Fuchs GJ, et al. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. *Urology* 2010 Sep;76(3):610-3.
<http://www.ncbi.nlm.nih.gov/pubmed/20163843>
60. Caoili EM, Bude RO, Higgins EJ, et al. Evaluation of sonographically guided percutaneous core biopsy of renal masses. *AJR Am J Roentgenol* 2002 Aug;179(2):373-8.
<http://www.ncbi.nlm.nih.gov/pubmed/12130435>
61. Chyhrai A, Sanjmyatav J, Gajda M, et al. Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. *World J Urol* 2010 Jun;28(3):269-74.
<http://www.ncbi.nlm.nih.gov/pubmed/20390284>
62. Eshed I, Elias S, Sidi AA. Diagnostic value of CT-guided biopsy of indeterminate renal masses. *Clin Radiol* 2004 Mar;59(3):262-7.
<http://www.ncbi.nlm.nih.gov/pubmed/15037139>
63. Hara I, Miyake H, Hara S, et al. Role of percutaneous image-guided biopsy in the evaluation of renal masses. *Urol Int* 2001;67(3):199-202.
<http://www.ncbi.nlm.nih.gov/pubmed/11598445>
64. Lechevallier E, André M, Barriol D, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. *Radiology* 2000 Aug;216(2):506-10.
<http://www.ncbi.nlm.nih.gov/pubmed/10924578>
65. Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. *AJR Am J Roentgenol* 2003 May;180(5):1281-7.
<http://www.ncbi.nlm.nih.gov/pubmed/12704038>

66. Sofikerim M, Tatlisen A, Canoz O, et al. What is the role of percutaneous needle core biopsy in diagnosis of renal masses? *Urology* 2010 Sep;76(3):614-8.
<http://www.ncbi.nlm.nih.gov/pubmed/20110106>
67. Somani BK, Nabi G, Thorpe P, et al. Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up. *Eur Urol* 2007 May;51(5):1289-95; discussion 1296-7.
<http://www.ncbi.nlm.nih.gov/pubmed/17081679>
68. Tan HJ, Jacobs BL, Hafez KS, et al. Understanding the role of percutaneous biopsy in the management of patients with a small renal mass. *Urology* 2012 Feb;79(2):372-7.
<http://www.ncbi.nlm.nih.gov/pubmed/22310755>
69. Vasudevan A, Davies RJ, Shannon BA, et al. Incidental renal tumours: the frequency of benign lesions and the role of preoperative core biopsy. *BJU Int* 2006 May;97(5):946-9.
<http://www.ncbi.nlm.nih.gov/pubmed/16643475>
70. Thuillier C, Long JA, Lapouge O, et al. [Value of percutaneous biopsy for solid renal tumours less than 4 cm in diameter based on a series of 53 cases]. *Prog Urol* 2008 Jul;18(7):435-9. [Article in French].
<http://www.ncbi.nlm.nih.gov/pubmed/18602603>
71. Shah RB, Bakshi N, Hafez KS, et al. Image-guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. *Hum Pathol* 2005 Dec;36(12):1309-15.
<http://www.ncbi.nlm.nih.gov/pubmed/16311125>
72. Reichelt O, Gajda M, Chyhray A, et al. Ultrasound-guided biopsy of homogenous solid renal masses. *Eur Urol* 2007 Nov;52(5):1421-6.
<http://www.ncbi.nlm.nih.gov/pubmed/17306920>
73. Torp-Pedersen S, Juul N, Larsen T, et al. US-guided fine needle biopsy of solid renal masses-- comparison of histology and cytology. *Scand J Urol Nephrol Suppl* 1991;137:41-3.
<http://www.ncbi.nlm.nih.gov/pubmed/1947839>
74. Jaff A, Molinié V, Mellot F, et al. Evaluation of imaging-guided fine-needle percutaneous biopsy of renal masses. *Eur Radiol* 2005 Aug;15(8):1721-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15627185>
75. Kroeze SG, Huisman M, Verkooijen HM, et al. Real-time 3D fluoroscopy-guided large core needle biopsy of renal masses: a critical early evaluation according to the IDEAL recommendations. *Cardiovasc Intervent Radiol* 2012 Jun;35(3):680-5.
<http://www.ncbi.nlm.nih.gov/pubmed/21822769>
76. Harisinghani MG, Maher MM, Gervais DA, et al. Incidence of malignancy in complex cystic renal masses (Bosniak category III): should imaging-guided biopsy precede surgery? *AJR Am J Roentgenol* 2003 Mar;180(3):755-8.
<http://www.ncbi.nlm.nih.gov/pubmed/12591691>
77. Lang EK, Macchia RJ, Gayle B, et al. CT-guided biopsy of indeterminate renal cystic masses (Bosniak 3 and 2F): accuracy and impact on clinical management. *Eur Radiol* 2002 Oct;12(10):2518-24.
<http://www.ncbi.nlm.nih.gov/pubmed/12271393>
78. Al Nazer M, Mourad WA. Successful grading of renal-cell carcinoma in fine-needle aspirates. *Diagn Cytopathol* 2000 Apr;22(4):223-6.
<http://www.ncbi.nlm.nih.gov/pubmed/10787141>
79. Amendola MA, Bree RL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. *Radiology* 1988 Mar;166(3):637-41.
<http://www.ncbi.nlm.nih.gov/pubmed/3277239>
80. Andonian S, Okeke Z, Okeke DA, et al. Number of needle passes does not correlate with the diagnostic yield of renal fine needle aspiration cytology. *J Endourol* 2008 Oct;22(10):2377-80.
<http://www.ncbi.nlm.nih.gov/pubmed/18937600>
81. Bielsa Gali O, Arango Toro O, Cortadellas Angel R, et al. [The preoperative diagnosis of complex renal cystic masses]. *Arch Esp Urol* 1999 Jan-Feb;52(1):19-25. [Article in Spanish].
<http://www.ncbi.nlm.nih.gov/pubmed/10101883>
82. Bishop JA, Hosler GA, Kulesza P, et al. *Diagn Cytopathol* 2011 Mar;39(3):168-71. Fine-needle aspiration of renal cell carcinoma: is accurate Fuhrman grading possible on cytologic material?
<http://www.ncbi.nlm.nih.gov/pubmed/21319316>
83. Brierly RD, Thomas PJ, Harrison NW, et al. Evaluation of fine-needle aspiration cytology for renal masses. *BJU Int* 2000 Jan;85(1):14-8.
<http://www.ncbi.nlm.nih.gov/pubmed/10619937>

84. Cajulis RS, Katz RL, Dekmezian R, et al. Fine needle aspiration biopsy of renal cell carcinoma. Cytologic parameters and their concordance with histology and flow cytometric data. *Acta Cytol* 1993 May-Jun;37(3):367-72.
<http://www.ncbi.nlm.nih.gov/pubmed/8498138>
85. Campbell SC, Novick AC, Herts B, et al. Prospective evaluation of fine needle aspiration of small, solid renal masses: accuracy and morbidity. *Urology* 1997 Jul;50(1):25-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9218014>
86. Civardi G, Cavanna L, Fornari F, et al. [Echographically guided, percutaneous, fine-needle puncture in the diagnosis of renal masses suspected of malignancy]. *Recenti Prog Med* 1986 Sep;77(9):420-2. [Article in Italian]. [No abstract available].
<http://www.ncbi.nlm.nih.gov/pubmed/3797794>
87. Cristallini EG, Paganelli C, Bolis GB. Role of fine-needle aspiration biopsy in the assessment of renal masses. *Diagn Cytopathol* 1991;7(1):32-5.
<http://www.ncbi.nlm.nih.gov/pubmed/2026081>
88. Elder DD, Orell SR, Sage MR, et al. The diagnosis and local staging of renal cancer--an appraisal. *Aust N Z J Surg* 1984 Jun;54(3):219-21.
<http://www.ncbi.nlm.nih.gov/pubmed/6590018>
89. García-Solano J, Acosta-Ortega J, Pérez-Guillermo M, et al. Solid renal masses in adults: image-guided fine-needle aspiration cytology and imaging techniques--"two heads better than one?". *Diagn Cytopathol* 2008 Jan;36(1):8-12.
<http://www.ncbi.nlm.nih.gov/pubmed/18064683>
90. Haubek A, Lundorf E, Lauridsen KN. Diagnostic strategy in renal mass lesions. *Scand J Urol Nephrol Suppl* 1991;137:35-9.
<http://www.ncbi.nlm.nih.gov/pubmed/1947838>
91. Izumi K, Narimoto K, Sugimoto K, et al. The role of percutaneous needle biopsy in differentiation of renal tumors. *Jpn J Clin Oncol* 2010 Nov;40(11):1081-6.
<http://www.ncbi.nlm.nih.gov/pubmed/20601495>
92. Johnson PT, Nazarian LN, Feld RI, et al. Sonographically guided renal mass biopsy: indications and efficacy. *J Ultrasound Med* 2001 Jul;20(7):749-53; quiz 755.
<http://www.ncbi.nlm.nih.gov/pubmed/11444733>
93. Juul N, Torp-Pedersen S, Grønvald S, et al. Ultrasonically guided fine needle aspiration biopsy of renal masses. *J Urol* 1985 Apr;133(4):579-81.
<http://www.ncbi.nlm.nih.gov/pubmed/3884841>
94. Karp W, Ekelund L. Ultrasound, angiography and fine needle aspiration biopsy in diagnosis of renal neoplasms. *Acta Radiol Diagn (Stockh)* 1979;20(4):649-59.
<http://www.ncbi.nlm.nih.gov/pubmed/525406>
95. Kelley CM, Cohen MB, Raab SS. Utility of fine-needle aspiration biopsy in solid renal masses. *Diagn Cytopathol* 1996 Feb;14(1):14-9.
<http://www.ncbi.nlm.nih.gov/pubmed/8834071>
96. Leiman G. Audit of fine needle aspiration cytology of 120 renal lesions. *Cytopathology* 1990;1(2):65-72.
<http://www.ncbi.nlm.nih.gov/pubmed/2102349>
97. Li G, Cuilleron M, Cottier M, et al. The use of MN/CA9 gene expression in identifying malignant solid renal tumors. *Eur Urol* 2006 Feb;49(2):401-5.
<http://www.ncbi.nlm.nih.gov/pubmed/16387417>
98. Masoom S, Venkataraman G, Jensen J, et al. Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology. *Cytopathology* 2009 Feb;20(1):50-5.
<http://www.ncbi.nlm.nih.gov/pubmed/18476991>
99. Mignon F, Mesurolle B, Ariche-Cohen M, et al. [Value of CT guided renal biopsies: retrospective review of 67 cases]. *J Radiol* 2001 Aug;82(8):907-11. [Article in French]
<http://www.ncbi.nlm.nih.gov/pubmed/11604686>
100. Mondal A, Ghosh E. Fine needle aspiration cytology (FNAC) in the diagnosis of solid renal masses--a study of 92 cases. *Indian J Pathol Microbiol* 1992 Oct;35(4):333-9.
<http://www.ncbi.nlm.nih.gov/pubmed/1344223>
101. Nadel L, Baumgartner BR, Bernardino ME. Percutaneous renal biopsies: accuracy, safety, and indications. *Urol Radiol* 1986;8(2):67-71.
<http://www.ncbi.nlm.nih.gov/pubmed/3024375>

102. Niceforo J, Coughlin BF. Diagnosis of renal cell carcinoma: value of fine-needle aspiration cytology in patients with metastases or contraindications to nephrectomy. *AJR Am J Roentgenol* 1993 Dec;161(6):1303-5.
<http://www.ncbi.nlm.nih.gov/pubmed/8249747>
103. Orell SR, Langlois SL, Marshall VR. Fine needle aspiration cytology in the diagnosis of solid renal and adrenal masses. *Scand J Urol Nephrol* 1985;19(3):211-6.
<http://www.ncbi.nlm.nih.gov/pubmed/3906863>
104. Pilotti S, Rilke F, Alasio L, Garbagnati F. The role of fine needle aspiration in the assessment of renal masses. *Acta Cytol* 1988 Jan-Feb;32(1):1-10.
<http://www.ncbi.nlm.nih.gov/pubmed/3336946>
105. Renshaw AA, Lee KR, Madge R, et al. Accuracy of fine needle aspiration in distinguishing subtypes of renal cell carcinoma. *Acta Cytol* 1997 Jul-Aug;41(4):987-94.
<http://www.ncbi.nlm.nih.gov/pubmed/9250289>
106. Richter F, Kasabian NG, Irwin RJ Jr, et al. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. *Urology* 2000 Mar;55(3):348-52.
<http://www.ncbi.nlm.nih.gov/pubmed/10699608>
107. Strojjan Fležar M, Gutnik H, Jeruc J, et al. Typing of renal tumors by morphological and immunocytochemical evaluation of fine needle aspirates. *Virchows Arch* 2011 Dec;459(6):607-14.
<http://www.ncbi.nlm.nih.gov/pubmed/22052200>
108. Tikkakoski T, Päivänsalo M, Apaja-Sarkkinen M, et al. Ultrasound-guided aspiration cytology of renal expansions. *Rontgenblatter* 1990 Dec;43(12):502-6.
<http://www.ncbi.nlm.nih.gov/pubmed/2287877>
109. Todd TD, Dhurandhar B, Mody D, et al. Fine-needle aspiration of cystic lesions of the kidney. Morphologic spectrum and diagnostic problems in 41 cases. *Am J Clin Pathol* 1999 Mar;111(3):317-28.
<http://www.ncbi.nlm.nih.gov/pubmed/10078106>
110. Truong LD, Todd TD, Dhurandhar B, et al. Fine-needle aspiration of renal masses in adults: analysis of results and diagnostic problems in 108 cases. *Diagn Cytopathol* 1999 Jun;20(6):339-49.
<http://www.ncbi.nlm.nih.gov/pubmed/10352906>
111. Zardawi IM. Renal fine needle aspiration cytology. *Acta Cytol* 1999 Mar-Apr;43(2):184-90.
<http://www.ncbi.nlm.nih.gov/pubmed/10097707>
112. Eble JN, Sauter G, Epstein JI, et al (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
113. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. *Urology* 2007 Feb;69(2):230-5.
<http://www.ncbi.nlm.nih.gov/pubmed/17275070>
114. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. *Hum Pathol* 2001 Jun;32(6):590-5.
<http://www.ncbi.nlm.nih.gov/pubmed/11431713>

4. CLASSIFICATION AND PROGNOSTIC FACTORS

4.1 Classification

The TNM classification system is generally recommended for clinical and scientific use (1). However, the system requires continuous improvements (2). The latest version of the TNM classification was published in 2010 (Table 6). The prognostic value of the 2010 TNM classification has been confirmed in both single and multi-institution studies (3,4). However, some uncertainties remain:

- The sub-classification of T1 tumours using a cut-off of 4 cm might not be optimal with the widening of nephron-sparing surgery for localised cancer.
- The value of size stratification of T2 tumours has been questioned (5).
- Since the 2002 version of the TNM classification, tumours with renal sinus fat invasion have been classified as pT3a. However, accumulating data suggest that renal sinus fat invasion carries a worse prognosis than perinephric fat invasion and therefore should not be included in the same pT3a stage group (LE: 3) (6-8).
- Some substages of the classification (pT2b, pT3a, pT3c and pT4) may overlap (4).
- The accuracy of the N1-N2 sub-classification has been questioned (9) (LE: 3). For adequate M staging

of patients with RCC, accurate preoperative imaging (currently, chest and abdominal CT) should be performed (10,11) (LE: 4).

4.2 Prognostic factors

Factors influencing prognosis can be classified into: anatomical, histological, clinical, and molecular.

4.2.1 Anatomical factors

Anatomical factors include tumour size, venous invasion, renal capsule invasion, adrenal involvement, and lymph node and distant metastasis. These factors are commonly gathered together in the universally used TNM classification system (Table 6).

Table 6: 2009 TNM classification system (1)

T - Primary tumour			
TX	Primary tumour cannot be assessed		
T0	No evidence of primary tumour		
T1	Tumour ≤ 7 cm in greatest dimension, limited to the kidney		
	T1a	Tumour ≤ 4 cm in greatest dimension, limited to the kidney	
	T1b	Tumour > 4 cm but ≤ 7 cm in greatest dimension	
T2	Tumour > 7 cm in greatest dimension, limited to the kidney		
	T2a	Tumour > 7 cm but ≤ 10 cm in greatest dimension	
	T2b	Tumours > 10 cm limited to the kidney	
T3	Tumour extends into major veins or directly invades adrenal gland or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia		
	T3a	Tumour grossly extends into the renal vein or its segmental (muscle-containing) branches or tumour invades perirenal and/or renal sinus (peripelvic) fat but not beyond Gerota's fascia	
	T3b	Tumour grossly extends into the vena cava below the diaphragm	
	T3c	Tumour grossly extends into vena cava above the diaphragm or invades the wall of the vena cava	
T4	Tumour invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)		
N - Regional lymph nodes			
NX	Regional lymph nodes cannot be assessed		
N0	No regional lymph node metastasis		
N1	Metastasis in a single regional lymph node		
N2	Metastasis in more than 1 regional lymph node		
M - Distant metastasis			
M0	No distant metastasis		
M1	Distant metastasis		
TNM stage grouping			
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
	T1, T2, T3	N1	M0
Stage IV	T4	Any N	M0
	Any T	N2	M0
	Any T	Any N	M1

A help desk for specific questions about TNM classification is available at <http://www.uicc.org/tnm>.

4.2.2 Histological factors

Histological factors include Fuhrman grade, RCC subtype, sarcomatoid features, microvascular invasion, tumour necrosis, and invasion of the collecting system. Fuhrman nuclear grade is the most widely accepted histological grading system in RCC (12). Although affected by intra- and inter-observer discrepancies, it is an independent prognostic factor (13). It has been suggested that a simplified two- or three-strata Fuhrman grading system could be as accurate as the classical four-tiered grading scheme (14,15) (LE: 3).

According to the WHO classification (16), three major histological subtypes of RCC exist: conventional (clear cell) (80-90%); papillary (10-15%); and chromophobe (4-5%). In univariate analysis, there is a trend towards a better prognosis for patients with chromophobe versus papillary versus conventional (clear cell) RCC

(17,18). However, the prognostic information provided by the RCC subtype is lost when stratified to tumour stage (18,19) (LE: 3).

Among papillary RCCs, two subgroups with different outcomes have been identified (20): Type 1 are low-grade tumours with a chromophilic cytoplasm and a favourable prognosis. Type 2 are mostly high-grade tumours with an eosinophilic cytoplasm and a great propensity for developing metastases (LE: 3).

RCC with Xp 11.2 translocation has been associated with a poor prognosis (21). Its incidence is low but should be systematically addressed in young patients.

The RCC type classification has been confirmed at the molecular level by cytogenetic and genetic analyses (22-24) (LE: 2b).

4.2.3 **Clinical factors**

Clinical factors include patient performance status, localised symptoms, cachexia, anaemia, and platelet count (25-28) (LE: 3).

4.2.4 **Molecular factors**

Numerous molecular markers being investigated, including: carbonic anhydrase IX (CaIX), vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF), Ki67 (proliferation), p53, PTEN (phosphatase and tensin homolog) (cell cycle), E-cadherin, C-reactive protein (CRP), osteopontin (29) and CD44 (cell adhesion) (30,31) (LE: 3). To date, none of these markers has been shown to improve the predictive accuracy of current prognostic systems and their use is therefore not recommended in routine practice. Finally, even though gene expression profiling seems a promising method, it has not helped so far to identify new relevant prognostic factors (32).

4.2.5 **Prognostic systems and nomograms**

Postoperative prognostic systems and nomograms that combine independent prognostic factors have been developed and externally validated (33-39). These systems may be more accurate than TNM stage or Fuhrman grade alone for predicting survival (LE: 3). An important advantage of nomograms is their ability to measure predictive accuracy (PA), which enables all new predictive parameters to be objectively evaluated. Before being adopted, every new prognostic variable or system should be able to demonstrate that its PA is superior to conventional postoperative histo-prognostic schemes (40). Recently, new preoperative nomograms with excellent PAs have been designed (41,42). Table 7 summarises the current most relevant prognostic systems.

4.3 **Conclusions**

	LE
In patients with RCC, TNM stage, nuclear grade according to Fuhrman, and RCC subtype (WHO, 2004; [21]), should be performed because they contribute important prognostic information.	2
Prognostic systems should currently be used in a metastatic setting and are still investigational in localised disease.	2

4.4 **Recommendations**

	GR
The current TNM classification system is recommended because it has consequences for prognosis and therapy.	B
The Fuhrman grading system and classification of RCC subtype should be used.	B
A stratification system should be used in a metastatic setting for selecting the appropriate first-line treatment.	B
In localised disease, the use of integrated prognostic systems or nomograms is not routinely recommended, even though these systems can provide a rationale for enrolling patients into clinical trials.	B
No molecular prognostic marker is currently recommended for routine clinical use.	B

Table 7: Summary of the anatomical, histological, and clinical variables included in the most commonly used prognostic models for localised and metastatic RCC

Prognostic Models		Variables												
		TNM Stage	ECOG PS	Karnofsky PS	RCC related symptoms	Fuhrman grade	Tumour necrosis	Tumour size	Delay between diagnosis and treatment	LDH	Corrected calcium	Hemoglobin	Neutrophil count	Platelet count
Localised RCC	UISS	X	X			X								
	SSIGN	X				X	X							
	Post operative Karakiewicz's nomogram	X			X	X	X							
Metastatic RCC	MSKCC prognostic system								X	X	X			
	Heng's model								X	X	X	X	X	X

ECOG PS = Eastern Cooperative Oncology Group performance status; LDH = lactate dehydrogenase; MSKCC = Memorial Sloan Kettering Cancer Center; PS = performance status; SSIGN = Stage Size Grade Necrosis; UISS = University of California Los Angeles integrated staging system.

4.5 References

1. Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009: pp. 255-257.
<http://www.uicc.org/tnm>
2. Gospodarowicz MK, Miller D, Groome PA, et al. The process for continuous improvement of the TNM classification. *Cancer* 2004 Jan;100(1):1-5.
<http://www.ncbi.nlm.nih.gov/pubmed/14692017>
3. Kim SP, Alt AL, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. *J Urol* 2011 Jun;185(6):2035-9.
<http://www.ncbi.nlm.nih.gov/pubmed/21496854>
4. Novara G, Ficarra V, Antonelli A, et al; SATURN Project-LUNA Foundation. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? *Eur Urol* 2010 Oct;58(4):588-95
<http://www.ncbi.nlm.nih.gov/pubmed/20674150>
5. Waalkes S, Becker F, Schrader AJ, et al. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? *Eur Urol* 2011 Feb;59(2):258-63.
<http://www.ncbi.nlm.nih.gov/pubmed/21030143>
6. Bertini R, Roscigno M, Freschi M, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. *J Urol* 2009 May;181(5):2027-32.
<http://www.ncbi.nlm.nih.gov/pubmed/19286201>
7. Poon SA, Gonzalez JR, Benson MC, et al. Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma. *BJU Int* 2009 Jun;103(12):1622-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19154464>
8. Bedke J, Buse S, Pritsch M, et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. *BJU Int* 2009 May;103(10):1349-54.
<http://www.ncbi.nlm.nih.gov/pubmed/19076147>
9. Terrone C, Cracco F, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. *Eur Urol* 2006 Feb;49(2):324-31.
<http://www.ncbi.nlm.nih.gov/pubmed/16386352>
10. Heidenreich A, Ravery V; European Society of Oncological Urology. Preoperative imaging in renal cell cancer. *World J Urol* 2004 Nov;22(5):307-15.
<http://www.ncbi.nlm.nih.gov/pubmed/15290202>
11. Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. *Radiographics* 2001 Oct;21. Spec No:S237-54.
<http://www.ncbi.nlm.nih.gov/pubmed/11598260>
12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982 Oct;6(7):655-63.
<http://www.ncbi.nlm.nih.gov/pubmed/7180965>
13. Lang H, Lindner V, de Fromont M, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. *Cancer* 2005 Feb;103(3):625-9.
<http://www.ncbi.nlm.nih.gov/pubmed/15611969>
14. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. *Cancer* 2007 Mar;109(5):868-74.
<http://www.ncbi.nlm.nih.gov/pubmed/17262800>
15. Sun M, Lughezzani G, Jeldres C, et al. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. *Eur Urol* 2009 Nov;56(5):775-81.
<http://www.ncbi.nlm.nih.gov/pubmed/19573980>
16. Eble JN, Sauter G, Epstein JI, et al (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyons: IARC Press, 2004, p. 7.
17. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histological subtypes of renal cell carcinoma. *Am J Surg Pathol* 2003 May;27(5):612-24.
<http://www.ncbi.nlm.nih.gov/pubmed/12717246>
18. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histological subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol* 2005 Apr;23(12):2763-71.
<http://www.ncbi.nlm.nih.gov/pubmed/15837991>

19. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int* 2009 Jun;103(11):1496-500.
<http://www.ncbi.nlm.nih.gov/pubmed/19076149>
20. Delahunt B, Eble JN, McCreddie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. *Hum Pathol* 2001 Jun;32(6):590-5.
<http://www.ncbi.nlm.nih.gov/pubmed/11431713>
21. Klatte T, Streubel B, Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. *Am J Clin Pathol* 2012 May;137(5):761-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22523215>
22. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. *Cancer Res* 2005 Jul;65(13):5628-37.
<http://www.ncbi.nlm.nih.gov/pubmed/15994935>
23. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease specific approaches to therapy. *Clin Cancer Res* 2004;10(18 Pt 2):6282S-9S.
<http://www.ncbi.nlm.nih.gov/pubmed/15448018>
24. Furge KA, Tan MH, Dykema K, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. *Oncogene* 2007 Feb;26(9):1346-50.
<http://www.ncbi.nlm.nih.gov/pubmed/17322920>
25. Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. *J Urol* 2006 Mar;175(3 Pt 1):859-63.
<http://www.ncbi.nlm.nih.gov/pubmed/16469566>
26. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. *J Urol* 2003 Nov;170(5):1742-6.
<http://www.ncbi.nlm.nih.gov/pubmed/14532767>
27. Kim HL, Han KR, Zisman A, et al. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. *J Urol* 2004 May;171(5):1810-3.
<http://www.ncbi.nlm.nih.gov/pubmed/15076282>
28. Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. *J Urol* 2004 Sep;172(3):858-62.
<http://www.ncbi.nlm.nih.gov/pubmed/15310983>
29. Sim SH, Messenger MP, Gregory WM, et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. *Br J Cancer* 2012 Sep 25;107(7):1131-7
<http://www.ncbi.nlm.nih.gov/pubmed/22918393>
30. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. *J Clin Oncol* 2009 Jun;27(16):2645-52.
<http://www.ncbi.nlm.nih.gov/pubmed/19364969>
31. Li G, Feng G, Gentil-Perret A, et al. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. *J Urol* 2008 Aug;180(2):510-3; discussion 513-4.
<http://www.ncbi.nlm.nih.gov/pubmed/18550116>
32. Zhao H, Ljungberg B, Grankvist K, et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. *PLoS Med* 2006 Jan;3(1):e13.
<http://www.ncbi.nlm.nih.gov/pubmed/16318415>
33. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol* 2005 Jan;173(1):48-51.
<http://www.ncbi.nlm.nih.gov/pubmed/15592023>
34. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol* 2001 Mar;19(6):1649-57.
<http://www.ncbi.nlm.nih.gov/pubmed/11250993>
35. Frank I, Blute ML, Chevillat JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol* 2002 Dec;168(6):2395-400.
<http://www.ncbi.nlm.nih.gov/pubmed/12441925>
36. Leibovich BC, Blute ML, Chevillat JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer* 2003 Apr;97(7):1663-71.
<http://www.ncbi.nlm.nih.gov/pubmed/12655523>

37. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. *J Clin Oncol* 2004 Aug;22(16):3316-22.
<http://www.ncbi.nlm.nih.gov/pubmed/15310775>
38. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. *J Clin Oncol* 2007 Apr;25(11):1316-22.
<http://www.ncbi.nlm.nih.gov/pubmed/17416852>
39. Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. *Eur Urol* 2010 Jan;57(1):102-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19062157>
40. Isbarn H, Karakiewicz PI. Predicting cancer-control outcomes in patients with renal cell carcinoma. *Curr Opin Urol* 2009 May;19(3):247-57.
<http://www.ncbi.nlm.nih.gov/pubmed/19325492>
41. Raj GV, Thompson RH, Leibovich BC, et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. *J Urol* 2008 Jun;179(6):2146-51; discussion 2151.
<http://www.ncbi.nlm.nih.gov/pubmed/18423735>
42. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. *Eur Urol* 2009 Feb; 55(2):287-95.
<http://www.ncbi.nlm.nih.gov/pubmed/18715700>

5. OTHER RENAL TUMOURS

Detailed morphological studies, which use contemporary immunohistochemical and molecular techniques, have resulted in the current classification of renal epithelial neoplasms, as outlined in the 2004 WHO monograph (1). A revised histopathological classification is expected in 2013. The common clear cell renal carcinoma (cRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC) types account for 85-90% of renal malignancies. The remaining 10-15% of renal tumours includes a variety of uncommon, sporadic, and familial carcinomas, some of which have recently been described, and a group of unclassified carcinomas.

5.1 Bellini duct carcinoma (collecting-duct carcinoma)

Collecting-duct carcinoma is a very rare type of RCC, often presenting at an advanced stage of disease. Up to 40% of patients have metastatic spread at initial presentation and most patients die within 1-3 years from the time of primary diagnosis. The hazard ratio in cancer specific survival is in comparison with cRCC 4.49 (2). To date, the largest case series (n = 81) to consider outcome showed that regional lymph node metastases were present in 44% of patients at diagnosis and distant metastases were present in 32%. The survival rate was 48% at 5 years and 14% at 10 years (3-5). Median survival was 30 months (6). Response to targeted therapies was poor (7).

5.2 Renal medullary carcinoma

Renal medullary carcinoma is a devastating malignancy that primarily affects young black men with sickle cell trait. However, case reports in white and Hispanic patients without sickle cell trait have emerged (3). Renal medullary carcinoma is considered to be a subtype of collecting duct carcinoma (8). It is extremely rare; comprising approximately 2% of all primary renal tumours in young people aged 10 to 20 years. Metastatic disease is seen at presentation in 95% of patients (3,9,10). Median survival is 5 months (6). Surgical intervention alone is inadequate (9), systemic therapy is not defined, different regimes of chemotherapy are used, and the tumour is radiosensitive. Due to the rarity of this tumour type, it is unlikely that a randomised trial can be carried out in a timely fashion (11).

5.3 Sarcomatoid RCC

Sarcomatoid RCC represents high-grade transformation in different RCC types, without being a distinct histological entity. Sarcomatoid changes in RCC carry a worse prognosis (12). The hazard ratio in cancer specific survival is in comparison with cRCC (2). Metastatic sarcomatoid RCC is associated with a poor response to systemic therapy. Sunitinib treatment resulted in a modest response rate (13). The combination of gemcitabine and doxorubicin could also be an option (14). (LE: 3) (GR: C).

5.4 Unclassified RCC

Unclassified RCC is a diagnostic category for RCC that cannot be assigned to any other category of RCC-type carcinoma (1).

5.5 Multilocular cystic RCC

There are no strict histopathological criteria for this subtype. In the WHO 2004 classification (1), multilocular cystic RCC is an independent entity, but it is essentially a well-differentiated clear cell RCC (15). This subtype accounts for up to approximately 3.5% of surgically treated kidney tumours (16). To date, metastases of this tumour have not been described (16,17). According to the Bosniak classification, which is based on imaging criteria, multilocular cystic RCC presents as a Bosniak type II or III cystic lesion (18-20). However, this type of Bosniak lesion can also be due to a mixed epithelial and stromal tumour of the kidney (MESTK), a cystic nephroma (both see section 5.11), or a multilocular cyst, all of which are benign lesions. In many cases, a pre-operative biopsy and intra-operative frozen-section analysis does not lead to a correct diagnosis. Fortunately, all these tumours are treated with the same operative strategy. For this reason, if technically feasible, a nephron-sparing procedure is the technique of choice for a complex multicystic renal mass when enhanced density is observed (LE: 3) (GR: B) (15-17, 19,20).

5.6 Papillary adenoma

Papillary adenomas are tumours with papillary or tubular architecture of low nuclear grade and are 5 mm in diameter or smaller (1). Because they are so small, they are only found incidentally in a nephrectomy specimen.

5.7 Translocation carcinoma (MITF/TFE family translocation-associated carcinoma)

Renal translocation carcinomas are uncommon tumours, which usually occur in children and young adults. Most translocation carcinomas (about 90%) involve the transcription factor E3 (TFE3) located on Xp11.2 and seem to follow a relatively indolent course, despite often being at an advanced stage at presentation, however, the clinical course is most aggressive in adults (3). Basically, there are 2 well-defined subtypes (ASPL/TFE3 and PRCC/TFE 3). VEGF-targeted agents appear to demonstrate some efficacy (21,22). Another rare group of RCCs that show a translocation [t(6; 11) (p21; q12)] has also been reported (3,23). A case report with a metastatic course and a partial response to sunitinib malate was described (24).

5.8 Mucinous tubular and spindle cell carcinoma

This tumour is associated with the loop of Henle. Most mucinous tubular and spindle-cell carcinomas behave in a low-grade fashion (1,3,25).

5.9 Carcinoma associated with end-stage renal disease

Acquired cystic disease-associated renal cell carcinoma, clear cell papillary RCC.

Cystic degenerative changes (acquired cystic kidney disease [ACKD]) and a higher incidence of RCC are typical features of ESKD (end-stage kidney disease). The incidence of ACKD is about 50% in patients undergoing dialysis, but also depends on the duration of dialysis, gender (three times more common in men), and the diagnostic criteria of the method of evaluation. RCCs of native end-stage kidneys are found in about 4% of patients. The lifetime risk of developing RCCs is at least 10 times higher than that in the general population. Compared with sporadic RCCs, the RCCs associated with ESKD and ACKD are characterised by multicentricity and bilaterality, are found in younger patients (mostly male), and have a less aggressive behaviour (26, 27). A relatively indolent outcome of tumours in ESKD is due only to the mode of diagnosis and not to specific ESKD-related molecular pathways still to be determined (27). RCC arising in native kidneys of transplant patients seems to exhibit many favourable clinical, pathological and outcome features compared with those diagnosed in dialysis-only patients. Further research is needed to determine whether this is due to particular molecular pathways or to biases in relation to mode of diagnosis (28). Although the histological spectrum of tumours within ACKD is similar to that in sporadic RCC, the most predominant form is pRCC, being found in 41-71% of ACKD-associated RCC versus 10% in sporadic RCC. The remaining tumours are mostly cRCC (3,26,27). Tickoo et al. (29) described two new renal tumours associated with ESKD: 'acquired cystic disease-associated RCC' and 'clear-cell pRCC'. To date, these two entities are under conscientious discussion. Clear cell (tubulo) pRCC has been reported in otherwise normal kidneys as well, and has low potential for malignancy (30, 31). The existence of ACKD-associated RCC is in dispute (27). Patients with ESKD should undergo an annual ultrasound evaluation of the kidneys. Minimally invasive radical nephrectomy can be performed safely in these patients (32).

5.10 Metanephric tumours

Metanephric tumours are divided into metanephric adenoma, adenofibroma, and metanephric stromal tumour. These are very rare benign tumours and surgical excision is sufficient (1).

5.11 Renal epithelial and stromal tumours

Renal epithelial and stromal tumours (REST) is a new concept that brings together two benign mixed mesenchymal and epithelial tumours: cystic nephroma and mixed epithelial and stromal tumours (33). Imaging studies have revealed that most REST cystic lesions are Bosniak type III and less frequently Bosniak type II or IV (18,20). Although aggressive behaviour has been reported in very few cases, both neoplasms are generally considered to be benign and surgical excision is curative (33).

5.12 Oncocytoma

Renal oncocytomas are benign tumours (1) that comprise about 3-7% of all renal tumours (34).

Imaging characteristics alone are unreliable when differentiating between oncocytoma and RCC.

Histopathological diagnosis remains the reference standard (35, 36). Although only a percutaneous biopsy can lead to a preoperative diagnosis, it has a low specificity for oncocytoma because oncocytotic cells are also found in cRCC, (the granular-cell variant of RCC), and in the eosinophilic variant of pRCC (type 2) and the oncocytic variant of pRCC. 'Watchful waiting' can be considered in selected cases of histologically verified oncocytoma. Alternative management includes partial nephrectomy and minimally invasive approaches. (LE: 3) (GR: C) (37,38).

5.13 Hereditary kidney tumours

Hereditary kidney tumours can be found as part of the following entities: Von Hippel-Lindau syndrome, hereditary pRCC, Birt-Hogg-Dubé syndrome (see Hybrid oncocytoma-chromophobe carcinoma), hereditary leiomyomatosis and renal cell cancer (HLRCC), tuberous sclerosis, and constitutional chromosome 3 translocation (1,39).

5.14 Mesenchymal tumours

Mesenchymal tumours include different types of benign tumours and sarcomas and are relatively rare, except for angiomyolipoma.

5.14.1 Angiomyolipoma

Angiomyolipoma (AML) is a benign mesenchymal tumour composed of a variable proportion of adipose tissue, spindle and epithelioid smooth muscle cells, and abnormal thick-walled blood vessels. It can occur sporadically, and is four times more likely in women. It also occurs in tuberous sclerosis (TS), when it is multiple, bilateral, larger, and likely to cause spontaneous haemorrhage. It accounts for approximately 1% of surgically removed tumours. Ultrasound, CT, and MRI often lead to diagnosis due to the presence of adipose tissue. Biopsy is rarely useful. Pre-operatively, it may be difficult to differentiate between tumours composed predominantly of smooth muscle cells and epithelial tumours. AML can be found in TS in lymph nodes, but it is not metastatic disease, but disease with a multicentric genesis. AML can be due to angiotropic-type growth involved in the renal vein even the inferior vena cava. AML with involvement of lymph nodes and tumorous thrombus is benign. Only epithelioid AML is a potentially malignant variant of AML (1, 40). AML is associated with a slow and consistent growth rate (0.088 cm/year), and typically has minimal morbidity (41). The main complications of renal AML are retroperitoneal bleeding or bleeding into the urinary collection system, which can be life-threatening (42). The bleeding tendency is related to the angiogenic component of the tumour that includes irregular and aneurysmatic blood vessels (42). The major risk factors for bleeding are tumour size, grade of the angiogenic component of the tumour, and the presence of tuberous sclerosis (42,43). Primary indications for intervention include symptoms such as pain, bleeding, or suspected malignancy.

Prophylactic intervention is justified for:

- large tumours (the recommended threshold of intervention does not exist, the formerly recommended size of > (3) 4 cm wide is disputed) (41, 42, 44);
- females of childbearing age;
- patients in whom follow-up or access to emergency care may be inadequate (43) (LE: 3) (GR: C).

Most cases of AML can be managed by conservative nephron-sparing approaches, although some cases of AML may require complete nephrectomy (43) (LE: 3). Of the standard surgical interventions, selective arterial embolisation (SAE) and radiofrequency ablation (RFA) can be used (41, 42, 44). Although SAE is effective at controlling haemorrhage in the acute setting, it has limited value in the longer-term management of AML (45). Clinical trials of medical management with m-TOR inhibitors are ongoing (46) and sirolimus can be combined with deferred surgery (47).

5.15 New histological entities

New histological entities have recently been described, for which there currently is very little clinical data. Some

of these entities are supposed to be included in a new ongoing histopathological classification. These entities include:

- Hybrid oncocytoma-chromophobe RCC
Hybrid oncocytic/chromophobe tumours (HOCT) of the kidney have been described for the first time in patients with Birt-Hogg-Dubé syndrome (a rare autosomal dominant syndrome characterised by skin hamartomas and multiple renal tumours) in association with renal oncocytosis. A sporadic variant also exists. The tumours seem to behave indolently as no evidence of malignant behaviour has been documented to date. However, these tumours could have a low malignant potential and patients should be followed-up as chromophobe RCC (48, 49).
- Oncocytic papillary renal cell carcinoma - type 3
This tumour could be termed a pRCC type 3. In comparison with pRCC type I and II, it has no pseudocapsule, no massive necroses, and extrarenal growth is relatively rare. The malignant potential is low (50).
- Tubulocystic renal cell carcinoma (TCRCC)
This occurs predominantly in men over a wide age range. There is a possible relationship to pRCC. It frequently displays a cystic component which may result in a radiological classification of Bosniak III or IV. TCRCC has definite malignant potential (51).
- thyroid-like follicular carcinoma of the kidney (52); rare tumour closely mimicking well-differentiated thyroid follicular neoplasms.
- RCC associated with neuroblastoma (1); extremely rare, morphologically heterogeneous entity.
- Renal angiomyoadenomatous tumour (53); the relation with clear cell pRCC (see above 5.9) is discussed (30,31,54).

Table 8: Summary of other renal tumours with an indication of malignant potential and recommendation for treatment (GR: C)

Entity	Malignant potential	Treatment of localised tumour
Sarcomatoid variants of RCC	High	Surgery
Multilocular clear cell RCC	Low, no metastasis	Surgery, NSS*
Carcinoma of the collecting ducts of Bellini	High, very aggressive	Surgery, in M+ discussable
Renal medullary carcinoma	High, very aggressive	Surgery
Translocation carcinoma	Intermediate	Surgery, NSS
Mucinous tubular and spindle cell carcinoma	Intermediate	Surgery, NSS
Carcinoma associated with end-stage renal disease	Variable	Surgery
Metanephric tumours	Benign	Surgery, NSS
Renal epithelial and stromal tumours (REST)	Low	Surgery, NSS
Oncocytoma	Benign	Observation/surgery, NSS
Hereditary kidney tumours	High	Surgery, NSS
Angiomyolipoma	Benign	Consider treatment only in very well selected patients
Unclassified RCC	Variable	Surgery, NSS

*NSS = *nephron-sparing surgery*.

5.16 Summary

A variety of renal tumours exists, of which about 15% are benign. All kidney lesions have to be examined (e.g. imaging, biopsy, etc.) and judged regarding the likelihood of malignant behaviour.

5.17 Recommendations

	LE	GR
Except for angiomyolipomas, most of these less common renal tumours cannot be differentiated from RCC on the basis of radiology and should therefore be treated in the same way as RCC.	3	C
Bosniak cysts \geq type III should be treated surgically. When possible, a nephron-sparing procedure should be performed in Bosniak type III.	3	C
In oncocytomas verified on biopsy, follow-up is an option.	3	C
In angiomyolipomas, treatment (surgery, thermal ablation, and selective arterial embolisation) can be considered in only very well selected cases. A nephron-sparing procedure is preferred.	3	C
In advanced uncommon types of renal tumours, a standardised oncological treatment approach does not exist.	4	C

5.18 References

- Eble JN, Sauter G, Epstein JI, et al (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004: p. 9-87.
- Keegan KA, Schupp CW, Chamie K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. *J Urol* 2012 Aug;188(2):391-7.
<http://www.ncbi.nlm.nih.gov/pubmed/22698625>
- Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. *Mod Pathol* 2009 Jun;22 Suppl 2:S2-S23.
<http://www.ncbi.nlm.nih.gov/pubmed/19494850>
- Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma in Japan: a nationwide survey in Japan. *J Urol* 2006 Jul;176(1):40-3.
<http://www.ncbi.nlm.nih.gov/pubmed/16753362>
- Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. *Eur Urol* 2007 Oct;52(4):1140-5.
<http://www.ncbi.nlm.nih.gov/pubmed/17336449>
- Abern MR, Tsivian M, Polascik TJ, et al. Characteristics and outcomes of tumors arising from the distal nephron. *Urology* 2012 Jul;80(1):140-6.
<http://www.ncbi.nlm.nih.gov/pubmed/22626576>
- Husillos A, Herranz-Amo F, Subirá D, et al. [Collecting duct renal cell carcinoma]. *Actas Urol Esp* 2011 Jun;35(6):368-71. [Article in Spanish].
<http://www.ncbi.nlm.nih.gov/pubmed/21450372>
- Gupta R, Billis A, Shah RB, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. *Am J Surg Pathol* 2012 Sep;36(9):1265-78.
<http://www.ncbi.nlm.nih.gov/pubmed/22895263>
- Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. *Urology* 2007 Nov;70(5):878-82.
<http://www.ncbi.nlm.nih.gov/pubmed/18068443>
- Watanabe IC, Billis A, Guimarães MS, et al. Renal medullary carcinoma: report of seven cases from Brazil. *Mod Pathol* 2007 Sep;20(9):914-20.
<http://www.ncbi.nlm.nih.gov/pubmed/17643096>
- Walsh AM, Fiveash JB, Reddy AT, et al. Response to radiation in renal medullary carcinoma. *Rare Tumors*. 2011 Jul 11;3(3):e32.
<http://www.ncbi.nlm.nih.gov/pubmed/22066039>
- de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. *Am J Surg Pathol* 2001 Mar;25(3):275-84.
<http://www.ncbi.nlm.nih.gov/pubmed/11224597>
- Molina AM, Tickoo SK, Ishill N, et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. *Am J Clin Oncol* 2011 Oct;34(5):454-9.
<http://www.ncbi.nlm.nih.gov/pubmed/21127411>
- Roubaud G, Gross-Goupil M, Wallerand H, et al. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. *Oncology* 2011;80(3-4):214-8.
<http://www.ncbi.nlm.nih.gov/pubmed/21720184>

15. Kuroda N, Ohe C, Mikami S, et al. Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. *Histol Histopathol* 2012 Aug;27(8):969-74.
<http://www.ncbi.nlm.nih.gov/pubmed/22763870>
16. Webster WS, Thompson RH, Cheville JC, et al. Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. *Urology* 2007 Nov;70(5):900-4. Discussion 904.
<http://www.ncbi.nlm.nih.gov/pubmed/18068445>
17. Gong K, Zhang N, He Z, et al. Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. *J Cancer Res Clin Oncol* 2008 Apr;134(4):433-7.
<http://www.ncbi.nlm.nih.gov/pubmed/17846788>
18. Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. *Urology* 2005 Sep;66(3):484-8. [no abstract available].
<http://www.ncbi.nlm.nih.gov/pubmed/16140062>
19. Limb J, Santiago L, Kaswick J, et al. Laparoscopic evaluation of indeterminate renal cysts: long-term follow-up. *J Endourol* 2002 Mar;16(2):79-82.
<http://www.ncbi.nlm.nih.gov/pubmed/11962559>
20. Hora M, Hes O, Michal M, et al. Extensively cystic renal neoplasms in adults (Bosniak classification II or III)-possible 'common' histological diagnoses: multilocular cystic renal cell carcinoma, cystic nephroma, and mixed epithelial and stromal tumor of the kidney. *Int Urol Nephrol* 2005 Dec;37(4):743-50.
<http://www.ncbi.nlm.nih.gov/pubmed/16362592>
21. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. *Cancer* 2010 Nov 15;116(22):5219-25.
<http://www.ncbi.nlm.nih.gov/pubmed/20665500>
22. Liu Y, Xu B, Chen F, et al. Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions. *N A J Med Sci* 2012;5(1): 43-7.
<http://www.najms.net/v5i1toc/>
23. Hora M, Hes O, Üрге T, et al. A Distinctive translocation carcinoma of the kidney ['rosette-like forming', t(6;11), HMB45 positive renal tumor]. *Int Urol Nephrol* 2009 Sep;41(3):553-7.
<http://www.ncbi.nlm.nih.gov/pubmed/18998233>
24. Ishihara A, Yamashita Y, Takamori H, et al. Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case. *Pathol Int* 2011 Sep;61(9):539-45.
<http://www.ncbi.nlm.nih.gov/pubmed/21884304>
25. Hes O, Hora M, Perez-Montiel DM, et al. Spindle and cuboidal renal cell carcinoma, a tumour having frequent association with nephrolithiasis: report of 11 cases including a case with hybrid conventional renal cell carcinoma/spindle and cuboidal renal cell carcinoma components. *Histopathol* 2002 Dec;41:549-55.
<http://www.ncbi.nlm.nih.gov/pubmed/12460208>
26. Hora M, Hes O, Reischig T, et al. Tumours in end-stage kidney. *Transplant Proc* 2008 Dec;40(10):3354-8.
<http://www.ncbi.nlm.nih.gov/pubmed/19100388>
27. Neuzillet Y, Tillou X, Mathieu R, et al; Comité de Transplantation de l'Association Française d'Urologie; Comité de Cancérologie de l'Association Française d'Urologie. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. *Eur Urol* 2011 Aug;60(2):366-73.
<http://www.ncbi.nlm.nih.gov/pubmed/21377780>
28. Gigante M, Neuzillet Y, Patard JJ, et al. The members of the Comité de Cancerologie de l'Association Française d'Urologie (CCAFU) and Comité de Transplantation de l'Association Française d'Urologie (CTAFU). Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? *BJU Int* 2012 Jun 22.
<http://www.ncbi.nlm.nih.gov/pubmed/22726451>
29. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasm in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histological pattern distinct from those in sporadic adult renal neoplasia. *Am J Surg Pathol* 2006 Feb;30(2):141-53.
<http://www.ncbi.nlm.nih.gov/pubmed/16434887>
30. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. *Am J Surg Pathol* 2010 Nov;34(11):1608-21.
<http://www.ncbi.nlm.nih.gov/pubmed/20924276>

31. Adam J, Couturier J, Molinié V, et al. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. *Histopathology* 2011 Jun;58(7):1064-71.
<http://www.ncbi.nlm.nih.gov/pubmed/21707708>
32. Klatte T, Marberger M. Renal cell carcinoma of native kidneys in renal transplant patients. *Curr Opin Urol.* 2011 Sep;21(5):376-9.
<http://www.ncbi.nlm.nih.gov/pubmed/21730855>
33. Montironi R, Mazzucchelli R, Lopez-Beltran A, et al. Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? *Eur Urol* 2008 Dec;54(6):1237-46.
<http://www.ncbi.nlm.nih.gov/pubmed/18006141>
34. Kuroda N, Toi M, Hiroi M, et al. Review of renal oncocytoma with focus on clinical and pathobiological aspects. *Histol Histopathol* 2003 Jul;18(3):935-42.
<http://www.ncbi.nlm.nih.gov/pubmed/12792905>
35. Choudhary S, Rajesh A, Mayer NJ, et al. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. *Clin Radiol* 2009 May;64(5):517-22.
<http://www.ncbi.nlm.nih.gov/pubmed/19348848>
36. Bird VG, Kanagarajah P, Morillo G, et al. Differentiation of oncocytoma and renal cell carcinoma in small renal masses (<4 cm): the role of 4-phase computerized tomography. *World J Urol* 2011 Dec;29(6):787-92.
<http://www.ncbi.nlm.nih.gov/pubmed/20717829>
37. Kurup AN, Thompson RH, Leibovich BC, et al. Renal oncocytoma growth rates before intervention. *BJU Int* 2012 Nov; 110(10):1444-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22520366>
38. Kawaguchi S, Fernandes KA, Finelli A, et al. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. *J Urol* 2011 Oct;186(4):1218-22.
<http://www.ncbi.nlm.nih.gov/pubmed/21849182>
39. Sanz-Ortega J, Olivier C, Pérez Segura P, et al. [Hereditary renal cancer]. *Actas Urol Esp* 2009 Feb;33(2):127-33. [Article in Spanish].
<http://www.ncbi.nlm.nih.gov/pubmed/19418834>
40. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. *Am J Surg Pathol* 2011 Feb;35(2):161-76.
<http://www.ncbi.nlm.nih.gov/pubmed/21263237>
41. Mues AC, Palacios JM, Haramis G, et al. Contemporary experience in the management of angiomyolipoma. *J Endourol* 2010 Nov;24(11):1883-6.
<http://www.ncbi.nlm.nih.gov/pubmed/20919915>
42. Ramon J, Rimon U, Garniek A, et al. Renal angiomyolipoma: long-term results following selective arterial embolization. *Eur Urol* 2009 May;55(5):1155-61.
<http://www.ncbi.nlm.nih.gov/pubmed/18440125>
43. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. *J Urol* 2002 Oct;168 (4 Pt 1):1315-25.
<http://www.ncbi.nlm.nih.gov/pubmed/12352384>
44. Oesterling JE, Fisham EK, Goldman SM, et al. The management of renal angiomyolipoma. *J Urol* 1986 Jun;135(6):1121-4. [No abstract available].
<http://www.ncbi.nlm.nih.gov/pubmed/3520013>
45. Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. *BJU Int* 2010 Jan;105(1):101-6.
<http://www.ncbi.nlm.nih.gov/pubmed/19493268>
46. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangiomyomatosis: a phase 2 trial. *Clin Cancer Res* 2011 Jun;17(12):4071-81.
<http://www.ncbi.nlm.nih.gov/pubmed/21525172>
47. Staehler M, Sauter M, Helck A, et al. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. *Int Urol Nephrol* 2012 Dec;44(6):1657-61.
<http://www.ncbi.nlm.nih.gov/pubmed/23054313>
48. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. *Virchows Arch* 2010 Apr;456(4):355-65.
<http://www.ncbi.nlm.nih.gov/pubmed/20300772>

49. Waldert M, Klatte T, Haitel A, et al. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. *Eur Urol* 2010 Apr;57(4):661-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19477583>
50. Urge T, Hes O, Ferda J, et al. Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis. *World J Urol* 2010 Aug; 28(4): 513-7.
<http://www.ncbi.nlm.nih.gov/pubmed/20454896>
51. Hora M, Urge T, Eret V, et al. Tubulocystic renal carcinoma: a clinical perspective. *World J Urol* 2011 Jun;29(3):349-54.
<http://www.ncbi.nlm.nih.gov/pubmed/21107846>
52. Amin MB, Gupta R, Ondrej H, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. *Am J Surg Pathol* 2009 Mar;33(3):393-400.
<http://www.ncbi.nlm.nih.gov/pubmed/19047894>
53. Michal M, Hes O, Nemcová J, et al. Renal angiomyoadenomatous tumor: morphologic, immunohistochemical and molecular genetic study of a new entity. *Virchows Arch* 2009 Jan;454(1): 89-99.
<http://www.ncbi.nlm.nih.gov/pubmed/19020896>
54. Michal M, Hes O, Kuroda N, et al. Difference between RAT and clear cell papillary renal cell carcinoma/clear renal cell carcinoma. *Virchows Arch* 2009 Jun;454(6):719.
<http://www.ncbi.nlm.nih.gov/pubmed/19471960>

6. TREATMENT OF LOCALISED RCC AND LOCAL TREATMENT OF METASTATIC RCC

A systematic review underpins the findings of sections 6.1 – 6.2. This review included all relevant published literature comparing surgical management of localised RCC (T1-2N0M0) (1,2). Randomised or quasi-randomised controlled trials (RCTs) were included. However, due to the very limited number of RCTs, non-randomised studies (NRS), prospective observational studies with controls, retrospective matched-pair studies, and comparative studies from well-defined registries databases were also included. Studies with no comparator group (for example, case series), unmatched retrospective studies, and chart reviews were excluded due to their inherent risk of selection bias. The systematic review methodology has been reported in detail elsewhere (1,2).

For sections 6.3 – 6.5, a traditional narrative review was performed (see Chapter 1).

For sections 6.6 – 6.7, a systematic review and narrative synthesis of the evidence was performed (see Chapter 1).

6.1 Main comparisons

6.1.1 *Surgery versus non-surgical treatment*

One matched pair study (derived from the SEER database) compared surgery for small renal masses (≤ 4 cm) with non-surgical management (3). Included were pT1a patients who were assigned to either observation or active surveillance. The analysis showed that surgical therapy had a significant 5 year cancer-specific mortality benefit over non-surgical intervention. However, even though this study was matched, it is marked by allocation bias; the patients assigned to the surveillance arm were older and likely more frail and less suitable candidates for surgery. There was no comparative study addressing this comparison in terms of perioperative and QoL outcomes.

6.1.2 *Nephron-sparing surgery versus radical nephrectomy*

Based on the available oncological and QoL outcomes, the current evidence suggests that localised renal cancers are best managed by nephron-sparing surgery (partial nephrectomy) rather than by radical nephrectomy, irrespective of the surgical approach.

When open partial nephrectomy was compared to open radical nephrectomy the estimated cancer-specific survival rates (CSS) at 5 years were comparable. (4-7). A number of studies compared partial against radical nephrectomy, either performed by an open or laparoscopic approach for renal carcinoma (≤ 4 cm) (8-11). These studies showed that radical nephrectomy was associated with increased mortality from any cause after adjusting for patient characteristics. In studies analysing RCCs 4-7 cm no differences were shown

for CSS between partial nephrectomy and radical nephrectomy (11-16). Also when laparoscopic partial nephrectomy and laparoscopic radical nephrectomy was compared in RCCs > 4 cm there was no difference in overall survival (OS), CSS and recurrence-free survival rates (RFS) (17).

In a number of studies various aspects of QoL and safety were compared for open partial and open radical nephrectomy (4-7,18-20). No difference in length of hospital stay (5,6,20), blood transfusions (5,18,20), or mean blood loss was found (5,20). In general, complication rates are inconsistently reported in NRS, and no clear conclusions in favour of one intervention over another can be drawn (21). The mean operative time was longer for the open partial group (20) but others found no such difference (22). Three studies consistently reported worse renal function after radical nephrectomy compared to partial nephrectomy (4,7,18). A greater proportion of patients had impaired postoperative renal function after radical nephrectomy after adjustment for diabetes, hypertension and age (7).

One database review compared open partial with laparoscopic radical nephrectomy in RCCs 4-7 cm (13). After partial nephrectomy, the mean increase of post-operative creatinine levels was significantly lower. When laparoscopic partial nephrectomy was compared to laparoscopic radical nephrectomy, the estimated GFR in the nephron-sparing group decreased less as compared to the radical nephrectomy group which showed a significantly greater proportion of patients with a 2-stage increase in the CKD stage (17). Another database review (23) compared laparoscopic partial with laparoscopic radical nephrectomy for RCCs > 4 cm in size. The laparoscopic radical nephrectomy group had a significantly greater decrease in estimated GFR and a greater proportion of patients with a CKD 2 stage.

Two studies reported QoL post-surgery for RCC. Patients who underwent partial nephrectomy reported better scores, in many aspects of quality of life (19). Those who underwent radical nephrectomy reported a higher degree of fear associated with living with only one kidney. Regardless of the intervention, patients with RCCs < 4 cm and a normal contralateral kidney showed the highest QoL scores after treatment, which matched their pre-diagnosis scores. Patients who had higher complications rates had lower QoL scores (5).

No comparative studies were identified reporting on oncological outcomes for minimally invasive ablative procedures compared with radical nephrectomy.

Patient and tumour characteristics permitting, the current oncological outcomes evidence base suggests that localised RCCs are best managed by NSS rather than by radical nephrectomy irrespective of surgical approach. Where open surgery is deemed necessary, the oncological outcomes following open NSS are at least as good as open radical nephrectomy and should be the preferred option when technically feasible. However, in some patients with localised RCC, NSS is not suitable because of:

- locally advanced tumour growth.
- partial resection is not technically feasible because the tumour is in an unfavourable location.
- significant deterioration of a patient's general health.

In these situations, the curative therapy remains radical nephrectomy, which includes removal of the tumour-bearing kidney. Complete resection of the primary tumour by either open or laparoscopic surgery offers a reasonable chance of curing the disease.

6.1.3 **Associated procedures**

6.1.3.1 *Adrenalectomy*

One prospective NRS compared the outcomes of radical or partial nephrectomy with, or without, ipsilateral adrenalectomy (24). On multivariate analysis, upper pole location was not predictive of adrenal involvement but tumour size proved significant. There was no difference in overall survival (OS) at 5 or 10 years, with, or without, adrenalectomy. Adrenalectomy was justified using criteria, based on radiographic and intra-operative findings. Only 48 of 2,065 patients underwent concurrent ipsilateral adrenalectomy of which 42 were for benign lesions.

6.1.3.2 *Lymph node dissection*

An extended or radical lymph node dissection does not appear to improve long-term survival following tumour nephrectomy (25). Thus, for staging purposes, lymph node dissection can be limited to the hilar region. In patients with palpable or CT-detected enlarged lymph nodes, resection of the affected lymph nodes should be performed to obtain adequate staging information.

6.1.3.3 *Embolisation*

Before a routine nephrectomy, there is no benefit in performing tumour embolisation (26,27). In patients who are unfit for surgery, or who present with non-resectable disease, embolisation can control symptoms such as gross haematuria or flank pain (28-30). Embolisation prior to the resection of hypervascular bone or spinal metastases can reduce intra-operative blood loss (31). In selected patients with painful bone or paravertebral

metastases, embolisation can help to relieve symptoms (32).

Conclusions	LE
Radical nephrectomy is no longer the standard treatment for low-stage RCC (T1).	3
There is an increased risk of intrarenal recurrences in larger-size (> 7 cm) tumours treated with nephron-sparing surgery, or when there is a positive margin.	3

Recommendations	LE	GR
Surgical therapy remains the mainstay of therapy to achieve a cure in the management of RCC.	C	
Patients with low-stage RCC (T1) should undergo nephron-sparing surgery rather than radical nephrectomy whenever possible.	3	B
Adrenalectomy is not recommended, provided a pre-operative CT scan shows the adrenal gland is normal and the intra-operative findings do not suggest intra-adrenal metastatic spread or a direct invasion of the adrenal gland.	3	C
Extended lymphadenectomy is not recommended since it does not appear to improve survival. It should be restricted to staging purposes with dissection of palpable and/or enlarged lymph nodes.	1b	A
In patients unfit for surgery and suffering from massive haematuria or flank pain, embolisation can be a beneficial palliative approach.		C
For solitary renal tumours up to a diameter of 7 cm, nephron-sparing surgery is the standard procedure, whenever technically feasible.	3	C
A minimal tumour-free surgical margin following partial resection of RCC is sufficient to avoid local recurrence.		B

6.2 Techniques of radical and partial nephrectomy

6.2.1 Techniques of radical nephrectomy

There are no randomised studies assessing oncological outcomes of laparoscopic versus open radical nephrectomy. A prospective cohort study (33) and a retrospective database review (5), both of low methodological quality, found similar oncological outcomes for laparoscopic versus open radical nephrectomy. Data from one RCT (34) and two NRSs (5,33) showed significantly shorter hospital stay and lower analgesic requirement for the laparoscopic radical nephrectomy group compared with the open group. Convalescence time was also significantly shorter (33). There was no difference in number of patients receiving a blood transfusion between the approaches but the perioperative blood loss was significantly less in the laparoscopic arm in all three studies (5,33,34). Surgical complications were marked by low event rates and very wide confidence intervals. There was no difference in complications but the operation time was significantly shorter in the open arm. Post-operative QoL scores were similar between the two groups (5).

In regard to the approach of performing radical nephrectomy, both retroperitoneal or transperitoneal approaches had similar oncologic outcomes in two RTCs (35,36) and one quasi-randomised study (37). There was no significant difference in quality of life variables between the two approaches.

Hand-assisted laparoscopic radical nephrectomy and standard laparoscopic radical nephrectomy was compared in one RCT (37) and one database review (21). Estimated 5-year overall survival, cancer-specific survival, and recurrence free survival rates were comparable between the approaches. Duration of operation was significantly shorter in the hand-assisted compared to the laparoscopic approach but length of hospital stay and time to non-strenuous activities were shorter for standard laparoscopic radical nephrectomy (21,37). However, the sample size was small.

Robot-assisted laparoscopic radical nephrectomy versus laparoscopic radical nephrectomy was compared in one small prospective cohort study (38). There were no local recurrences, port-site or distant metastases, but sample size was small and follow-up was less than 1 year. Similar results were presented in observational cohort studies comparing 'portless' (n = 14) and 3-port (n = 15) laparoscopic radical nephrectomy (39,40). There was no difference in perioperative outcomes.

6.2.2 Techniques of partial nephrectomy and minimally invasive ablative procedures

Laparoscopic partial nephrectomy compared to open partial nephrectomy showed no difference in overall survival (41-44). Regarding the number of deaths during the study period, a lower risk of all cause death was shown in the laparoscopic group in one study (42) while in other studies no difference in the recurrence patterns between laparoscopic and open partial nephrectomy was reported (41,44). In a matched pair analysis (43) the length of hospital stay was significantly shorter and there was less mean blood loss in the laparoscopic

partial group. In one database review more blood transfusion events occurred in the laparoscopic group (41). There were no differences between the groups in postoperative mortality events (41,43), DVT events (43), or pulmonary embolism events but the operative time was significantly longer in the laparoscopic partial group (22,43,44). Decline in GFR was greater in the laparoscopic partial nephrectomy group in the immediate postoperative period (44), but not after a follow-up of 3.6 years.

There is no comparative study that reported on oncological outcomes between robotic assisted partial nephrectomy and laparoscopic partial nephrectomy. One study based on a matched-pair analysis (45) showed no difference in perioperative outcomes (10) or in the estimated GFR.

In regard to partial nephrectomy versus minimally invasive ablative procedures, several studies were identified. For radiofrequency-assisted robotic partial nephrectomy versus laparoscopic partial nephrectomy, a database review (46) found no differences between the groups in terms of positive surgical margins and recurrence rates, but the study was marked by very low event rates, a high number of benign tumours, and short-term survival data.

Data on laparoscopic cryoablation versus laparoscopic partial nephrectomy obtained from one database review (47) reported 3 deaths out of 78 patients treated, compared with none out of 153 patients treated with laparoscopic partial nephrectomy. In another matched pair study no recurrences were reported in either treatment but with a follow-up of less than 12 months (48). It should be noted that the studies also included benign tumours and the data should be treated with caution. In a database review (47) and a matched-pair study (48) there were no differences in perioperative outcomes, recovery times, complication rates or postoperative serum creatinine levels between laparoscopic cryoablation and laparoscopic partial nephrectomy. Blood loss was less and surgical time was quicker in the cryoablation group than the laparoscopic partial nephrectomy group (47,48). In one matched comparison between laparoscopic cryoablation and open partial nephrectomy (49) no local recurrences or metastasis was found in either group. The length of hospital stay was shorter and the mean blood loss was significantly less in the laparoscopic cryoablation group, but there was no difference in number of patients requiring blood transfusions or duration of operation. However, there were only 20 patients in each arm and the follow-up time was short.

Conclusions	LE
Laparoscopic radical nephrectomy appears to have a lower morbidity compared to open surgery.	1a
Tumour control rates appear equivalent for T1-T2 tumours between laparoscopic and open radical nephrectomy.	3
Long-term outcome data indicate that laparoscopic radical nephrectomy has equivalent cancer-free survival rates to those of open radical nephrectomy.	3
Partial nephrectomy by laparoscopic surgery is technically feasible.	3
The data regarding quality of life and perioperative outcomes for laparoscopic nephron-sparing surgery compared with open nephron-sparing surgery remains.	3

Recommendations	LE	GR
Laparoscopic radical nephrectomy is recommended in T2 renal cell cancer.		C
Laparoscopic radical nephrectomy is the standard of care for patients with T2 tumours and those renal masses not treatable by nephron-sparing surgery.		C
Laparoscopic radical nephrectomy should not be performed in patients with T1 tumours for whom partial nephrectomy is indicated.	3	C
Extended lymphadenectomy is not recommended since it does not appear to improve survival. It should be restricted to staging purposes with dissection of palpable and/or enlarged lymph nodes.	1b	A
Laparoscopic and robot assisted partial nephrectomy is an alternative to open nephron-sparing surgery.		C
Open partial nephrectomy currently remains as a standard of care for partial nephrectomy.		C

6.3 Therapeutic approaches as alternatives to surgery

6.3.1 Surveillance

Elderly and co-morbid patients with incidentally detected small renal masses have a relatively low RCC-specific mortality and a significant competing-cause mortality (50,51).

Active surveillance is defined as the initial monitoring of tumour size by serial abdominal imaging (ultrasound, CT, or MRI) with delayed intervention reserved for those tumors that show clinical progression during follow-up (52).

In the largest reported series of active surveillance the growth of renal tumors is low in the majority of

cases and progression to metastatic disease is reported in a limited number of patients (1-2%) (53,54). Both short- and intermediate-term oncological outcomes indicate that in selected patients with advanced age and/or comorbidities, active surveillance is an appropriate strategy to initially monitor small renal masses and if required by treatment for progression (52-58).

6.4 Adjuvant therapy

Current evidence that adjuvant tumour vaccination might improve the duration of the progression-free survival of selected subgroups of patients undergoing nephrectomy for T3 renal carcinomas needs further confirmation regarding the impact on overall survival (LE: 1b) (59-63). Prognostic algorithms might identify patients likely to derive the largest clinical benefit from adjuvant vaccination therapy.

Conclusions	LE
Active surveillance is defined as the initial monitoring of tumour size by serial abdominal imaging (ultrasound, CT, or MRI) with delayed intervention reserved for those tumors that show clinical progression during follow-up.	3
Adjuvant therapy with cytokines does not improve survival after nephrectomy.	1b

Recommendations	GR
Active surveillance is a reasonable option for elderly and/or comorbid patients with small renal masses and limited life expectancy.	C
Patients with small renal tumours and/or significant co-morbidity who are unfit for surgery should be considered for an ablative approach, e.g. cryotherapy and radiofrequency ablation.	C
Pre-treatment biopsy has to be carried out as a standard before ablative therapy and is useful when active surveillance is considered and in order to stratify follow-up based on tumor histology.	C
Other image-guided percutaneous and minimally invasive techniques, such as microwave ablation, laser ablation, and high-intensity focused ultrasound ablation are experimental and are recommended only in studies.	C
Outside controlled clinical trials, there is no indication for adjuvant therapy following surgery.	A

6.5 Surgical treatment of metastatic RCC (tumour nephrectomy or cytoreductive nephrectomy)

Tumour nephrectomy is curative only if surgery can excise all tumour deposits. For the majority of patients with metastatic disease, cytoreductive nephrectomy is palliative and systemic treatments are necessary. In a meta-analysis of two randomized studies, comparing cytoreductive nephrectomy combined with immunotherapy versus immunotherapy only, an increased long-term survival was found in patients subjected to cytoreductive nephrectomy (64). At present, only limited data are available addressing the value of cytoreductive nephrectomy combined with targeting agents such as sunitinib, sorafenib and others. Randomised studies are ongoing.

Conclusions	LE
Tumour nephrectomy in combination with interferon-alpha (IFN- α) improves the survival of patients with metastatic RCC (mRCC) and good performance status.	1a

Recommendations	GR
Tumour nephrectomy is recommended for metastatic RCC patients with good performance status when combined with IFN-alpha.	A

6.6 Surgical resection of metastases in metastatic RCC

A systematic review was undertaken (65). No randomised trials were identified comparing metastasectomy with other treatments, but 12 non-randomised comparative studies involving metastasectomy were identified. A number of studies compared complete metastasectomy with partial metastasectomy in patients with metastatic RCC involving multiple organ sites (66-68). The results showed an overall survival advantage for complete resection. When complete metastasectomy was compared with no surgical resection (69-71), complete metastasectomy offered a slight overall survival advantage.

In the treatment of bone metastases, metastasectomy in combination with local stabilization provided a significant survival advantage over that of non-surgical treatment (72).

In visceral metastases affecting the liver and pancreas, metastasectomy showed a significantly prolonged overall survival compared with non-surgical treatment (73,74). For patients with liver metastases, radical resection was associated with significantly better overall survival compared with either partial resection or ablation (75).

For the treatment of brain lesions, one study compared metastasectomy followed by whole brain radiotherapy, against fractionated stereotactic radiotherapy or conventional radiotherapy alone (76). There was no difference in cancer specific survival, although surgery appeared to offer some benefits regarding local tumour control.

6.7 Radiotherapy for metastases in metastatic RCC

A systematic review was undertaken (65). Three non-randomised comparative studies involving different radiotherapy modalities were identified. The results showed there was no significant survival benefit using radiotherapy. However, there was evidence of improved local tumour control with radiotherapy. Two studies (77,78) involving bone metastases showed an improvement in bone pain using different radiotherapy modalities. In a study on brain metastases (79) whole brain radiotherapy alone, stereotactic radiosurgery alone or a combination of the two were compared. The study showed a good local tumour control using either individual modality in patients with 1-3 metastases to the brain.

Conclusions	LE
There is a definite role for metastasectomy in patients with RCC in order to improve the clinical prognosis. Its role has to be continuously re-evaluated, especially in combination with targeted systemic therapy.	3
Radiotherapy to bone and brain metastases from RCC can induce significant relief from local symptoms (e.g. pain).	3

Recommendations	GR
In patients with metastatic spread, metastasectomy should be performed where disease is resectable and the patient has a good performance status.	C
Metastasectomy should be performed in patients with residual and resectable metastatic lesions previously responding to immunotherapy and/or other systemic treatment.	C
In individual cases, stereotactic radiotherapy for the treatment of bone and brain metastases can induce symptom relief.	C

6.8 References

- MacLennan S, Imamura M, Lapitan MC, et al; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. *Eur Urol* 2012 Dec;62(6):1097-117.
<http://www.ncbi.nlm.nih.gov/pubmed/22841673>
- MacLennan S, Imamura M, Lapitan MC, et al; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of oncological outcomes following surgical management of localised renal cancer. *Eur Urol* 2012 May;61(5):972-93. Jul;62(1):193.
<http://www.ncbi.nlm.nih.gov/pubmed/22405593>
- Zini L, Perrotte P, Jeldres C, et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. *BJU Int* 2009 Apr;103(7):899-904.
<http://www.ncbi.nlm.nih.gov/pubmed/19154499>
- Butler BP, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. *Urology* 1995 Jan;45(1):34-40.
<http://www.ncbi.nlm.nih.gov/pubmed/7817478>
- Gratzke C, Seitz M, Bayrle F, et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. *BJU Int* 2009 Aug;104(4):470-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19239445>
- D'Armiento M, Damiano R, Feleppa B, et al. Elective conservative surgery for renal carcinoma versus radical nephrectomy: a prospective study. *Br J Urol* 1997 Jan;79(1):15-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9043488>
- Lee JH, You CH, Min GE et al. Comparison of the surgical outcome and renal function between radical and nephron-sparing surgery for renal cell carcinomas. *Korean J Urol* 2007; 48:671-676.

8. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? *J Urol* 2009 Jan;181(1):55-61.
<http://www.ncbi.nlm.nih.gov/pubmed/19012918>
9. Zini L, Perrotte P, Capitanio U, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer* 2009 Apr;115(7):1465-71.
<http://www.ncbi.nlm.nih.gov/pubmed/19195042>
10. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. *J Urol* 2008 Feb;179(2):468-71.
<http://www.ncbi.nlm.nih.gov/pubmed/18076931>
11. Patard JJ, Bensalah KC, Pantuck AJ, et al. Radical nephrectomy is not superior to nephron sparing surgery in PT1B-PT2N0M0 renal tumours: A matched comparison analysis in 546 cases. *Eur Urol Suppl* 2008;7:194.
12. Thompson RH, Kaag M, Vickers A, et al. Contemporary use of partial nephrectomy at a tertiary care center in the United States. *J Urol* 2009 Mar;181(3):993-7.
<http://www.ncbi.nlm.nih.gov/pubmed/19150552>
13. Dash A, Vickers AJ, Schachter LR, et al. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. *BJU Int* 2006 May; 97(5):939-45.
<http://www.ncbi.nlm.nih.gov/pubmed/16643474>
14. Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. *J Urol* 2010 Apr;183(4):1317-23.
<http://www.ncbi.nlm.nih.gov/pubmed/20171688>
15. Crépel M, Jeldres C, Perrotte P, et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. *Urology* 2010 Feb;75(2):271-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19962740>
16. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. *J Urol* 2004 Jun;171(6 Pt 1):2181-5.
<http://www.ncbi.nlm.nih.gov/pubmed/15126781>
17. Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. *Urology* 2009 May;73(5):1077-82.
<http://www.ncbi.nlm.nih.gov/pubmed/19394509>
18. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol* 2007 Jun; 51(6):1606-15.
<http://www.ncbi.nlm.nih.gov/pubmed/17140723>
19. Poulakis V, Witzsch U, de Vries R, et al. Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery. *Urology* 2003 Nov;62(5): 814-20.
<http://www.ncbi.nlm.nih.gov/pubmed/14624900>
20. Shekarriz B, Upadhyay J, Shekarriz H, et al. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. *Urology* 2002 Feb; 59(2):211-15.
<http://www.ncbi.nlm.nih.gov/pubmed/11834387>
21. Gabr AH, Gdor Y, Strobe SA, et al. Approach and specimen handling do not influence oncological perioperative and long-term outcomes after laparoscopic radical nephrectomy. *J Urol* 2009 Sep;182(3):874-80.
<http://www.ncbi.nlm.nih.gov/pubmed/19616234>
22. Imamura M, MacLennan S, Lapitan MC, et al. Systematic review of the clinical effectiveness of surgical management for localised renal cell carcinoma. University of Aberdeen, Academic Urology Unit ,2011. Aberdeen, UK. Available from:
<http://www.uroweb.org/?id=217&tyid=1&oid=4>.
23. Simmons MN, Chung BI, Gill IS. Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm. *Eur Urol* 2009 Jan;55(1):199-208.
<http://www.ncbi.nlm.nih.gov/pubmed/18684555>
24. Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. *J Urol* 2009 Jun; 181(6):2430-6.
<http://www.ncbi.nlm.nih.gov/pubmed/19371896>

25. Blom JH, Van Poppel H, Maréchal JM, et al. Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. *Eur Urol* 2009 Jan;55(1):28-34.
<http://www.ncbi.nlm.nih.gov/pubmed/18848382>
26. May M, Brookman-Amissah S, Pflanz S, et al. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. *Br J Radiol* 2009 Aug;82(981):724-31.
<http://www.ncbi.nlm.nih.gov/pubmed/19255117>
27. Subramanian VS, Stephenson AJ, Goldfarb DA, et al. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. *Urology* 2009 Jul;74(1):154-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19428069>
28. Maxwell NJ, Saleem Amer N, Rogers E, et al. Renal artery embolization in the palliative treatment of renal carcinoma. *Br J Radiol* 2007 Feb;80(950):96-102.
<http://www.ncbi.nlm.nih.gov/pubmed/17495058>
29. Hallscheidt P, Besharati S, Noeldge G, et al. Preoperative and palliative embolization of renal cell carcinomas: follow-up of 49 patients. *Rofo* 2006 Apr;178(4):391-9.
<http://www.ncbi.nlm.nih.gov/pubmed/16612730>
30. Lamb GW, Bromwich EJ, Vasey P, et al. Management of renal masses in patients medically unsuitable for nephrectomy—natural history, complications and outcome. *Urology* 2004 Nov;64(5):909-13.
<http://www.ncbi.nlm.nih.gov/pubmed/15533476>
31. Kickuth R, Waldherr C, Hoppe H, et al. Interventional management of hypervascular osseous metastasis: role of embolotherapy before orthopedic tumor resection and bone stabilization. *AJR Am J Roentgenol* 2008 Dec;191(6):W240-7.
<http://www.ncbi.nlm.nih.gov/pubmed/19020210>
32. Forauer AR, Kent E, Cwikiel W, et al. Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma. *Acta Oncol* 2007;46(7):1012-18.
<http://www.ncbi.nlm.nih.gov/pubmed/17851849>
33. Hemal AK, Kumar A, Kumar R, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. *J Urol* 2007 Mar;177(3):862-6.
<http://www.ncbi.nlm.nih.gov/pubmed/17296361>
34. Peng B, Zheng J-H, Xu D-F, Ren J-Z. Retroperitoneal laparoscopic nephrectomy and open nephrectomy for radical treatment of renal cell carcinoma: A comparison of clinical outcomes. *Academic Journal of Second Military Medical University* 2006;27:1167-9.
35. Desai MM, Strzempkowski B, Matin SF, et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. *J Urol* 2005 Jan;173(1):38-41.
<http://www.ncbi.nlm.nih.gov/pubmed/15592021>
36. Nambirajan T, Jeschke S, Al-Zahrani H et al. Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. *Urology* 2004 Nov;64(5):919-24.
<http://www.ncbi.nlm.nih.gov/pubmed/15533478>
37. Nadler RB, Loeb S, Clemens JQ et al. A prospective study of laparoscopic radical nephrectomy for T1 tumors--is transperitoneal, retroperitoneal or hand assisted the best approach? *J Urol* 2006 Apr;175(4):1230-3.
<http://www.ncbi.nlm.nih.gov/pubmed/16515966>
38. Hemal AK, Kumar A. A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. *World J Urol* 2009 Feb;27(1):89-94.
<http://www.ncbi.nlm.nih.gov/pubmed/18704439>
39. Soga N, Kato M, Masui S, et al. Comparison of radical nephrectomy techniques in one center: Minimal incision portless endoscopic surgery versus laparoscopic surgery. *Int J Urol* 2008 Oct; 15(11): 1018-21.
<http://www.ncbi.nlm.nih.gov/pubmed/19138194>
40. Park Y, Lee S, Ku J et al. Laparoendoscopic single-site radical nephrectomy for localized renal cell carcinoma: comparison with conventional laparoscopic surgery. *J Endourol* 2009; 23(Suppl):A19.
41. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. *J Urol* 2007 Jul;178(1):41-6.
<http://www.ncbi.nlm.nih.gov/pubmed/17574056>
42. Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. *J Urol* 2010 Feb;183(2):473-9.
<http://www.ncbi.nlm.nih.gov/pubmed/20006866>

43. Gong EM, Orvieto MA, Zorn KC, et al. Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. *J Endourol* 2008 May;22(5):953-7.
<http://www.ncbi.nlm.nih.gov/pubmed/18363510>
44. Marszalek M, Meixl H, Polajnar M, et al. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 Patients. *Eur Urol* 2009 May;55(5):1171-8.
<http://www.ncbi.nlm.nih.gov/pubmed/19232819>
45. Aron M, Koenig P, Kaouk JH, et al. Robotic and laparoscopic partial nephrectomy: a matched-pair comparison from a high-volume centre. *BJU Int* 2008 Jul;102(1):86-92.
<http://www.ncbi.nlm.nih.gov/pubmed/18336600>
46. Wu SD, Viprakasit DP, Cashy J, et al. Radiofrequency ablation-assisted robotic laparoscopic partial nephrectomy without renal hilar vessel clamping versus laparoscopic partial nephrectomy: a comparison of perioperative outcomes. *J Endourol* 2010 Mar;24(3):385-91.
<http://www.ncbi.nlm.nih.gov/pubmed/20334556>
47. Desai MM, Aron M, Gill IS. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor. *Urology* 2005 Nov;66(5 Suppl):23-8.
<http://www.ncbi.nlm.nih.gov/pubmed/16194703>
48. O'Malley RL, Berger AD, Kanofsky JA, et al. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. *BJU Int* 2007 Feb;99(2):395-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17092288>
49. Ko YH, Park HS, Moon du G, et al. A matched-cohort comparison of laparoscopic renal cryoablation using ultra-thin cryoprobes with open partial nephrectomy for the treatment of small renal cell carcinoma. *Cancer Res Treat* 2008 Dec;40(4):184-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19688128>
50. Lane BR, Abouassaly R, Gao T, Et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. *Cancer* 2010 Jul;116(13):3119-26.
<http://www.ncbi.nlm.nih.gov/pubmed/20564627>
51. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. *Cancer* 2007 May;109(9):1763-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17351954>
52. Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. *Cancer* 2004 Feb;100(4):738-45.
<http://www.ncbi.nlm.nih.gov/pubmed/14770429>
53. Jewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. *Eur Urol* 2011 Jul;60(1):39-44.
<http://www.ncbi.nlm.nih.gov/pubmed/21477920>
54. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. *Cancer* 2011 Feb;118(4):997-1006.
<http://www.ncbi.nlm.nih.gov/pubmed/21766302>
55. Abou Youssif T, Kassouf W, Steinberg J, et al. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. *Cancer* 2007 Sep;110(5):1010-4.
<http://www.ncbi.nlm.nih.gov/pubmed/17628489>
56. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. *J Urol* 2008 Aug;180(2):505-8; discussion 8-9.
<http://www.ncbi.nlm.nih.gov/pubmed/18550113>
57. Crispin PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. *Cancer* 2009 Jul;115(13):2844-52.
<http://www.ncbi.nlm.nih.gov/pubmed/19402168>
58. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. *J Urol* 2010 May;183(5):1698-702.
<http://www.ncbi.nlm.nih.gov/pubmed/20299038>
59. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. *Cancer* 1996 Jun;77(12):2560-6.
<http://www.ncbi.nlm.nih.gov/pubmed/8640706>
60. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol* 1999 Aug;17(8):2521-9.
<http://www.ncbi.nlm.nih.gov/pubmed/10561318>

61. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. *J Clin Oncol* 2003 Aug;21(16):3133-40. <http://www.ncbi.nlm.nih.gov/pubmed/12810695>.
62. Atzpodien J, Schmitt E, Gertenbach U, et al; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemioimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *Br J Cancer* 2005 Mar;92(5):843-6. <http://www.ncbi.nlm.nih.gov/pubmed/15756254>
63. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. *Lancet* 2004 Feb;363(9409):594-9. <http://www.ncbi.nlm.nih.gov/pubmed/14987883>
64. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 2004 Mar;171(3):1071-6. <http://www.ncbi.nlm.nih.gov/pubmed/14767273>
65. Dabestani S, Hofmann F, Marconi L, et al, EAU Renal Cell Carcinoma Guideline Panel. Systematic review methodology for the EAU RCC Guideline 2013 update. http://www.uroweb.org/gls/refs/Systematic_methodology_RCC_2013_update.pdf
66. Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. *Cancer* 2011 Jul;117(13):2873-82. <http://www.ncbi.nlm.nih.gov/pubmed/21692048>
67. Russo P, Synder M, Vickers A, et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. *ScientificWorldJournal*. 2007 Feb;7:768-78. <http://www.ncbi.nlm.nih.gov/pubmed/17619759>
68. Steiner T, Kirchner H, Siebels M, et al. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. *J Cancer Res Clin Oncol* 2010 Jun;136(6):905-10. <http://www.ncbi.nlm.nih.gov/pubmed/20012752>
69. Brinkmann OA, Semik M, Goshgerger G, et al. The role of residual tumor resection in patients with metastatic renal cell carcinoma and partial remission following immunotherapy. *Eur Urol* 2007; Suppl 6:641-5.
70. Lee SE, Kwak C, Byun SS, et al. Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma. *Urol Int* 2006;76(3):256-63. <http://www.ncbi.nlm.nih.gov/pubmed/16601390>
71. Kwak C, Park YH, Jeong CW, et al. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. *Urol Int* 2007;79(2):145-51. <http://www.ncbi.nlm.nih.gov/pubmed/17851285>
72. Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. *Clin Orthop Relat Res* 2005 Feb;(431):187-92. <http://www.ncbi.nlm.nih.gov/pubmed/15685074>
73. Zerbi A, Ortolano E, Balzano G, et al. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? *Ann Surg Oncol* 2008 Apr;15(4):1161-8. <http://www.ncbi.nlm.nih.gov/pubmed/18196343>
74. Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. *World J Urol* 2010 Aug;28(4):543-7. <http://www.ncbi.nlm.nih.gov/pubmed/20440505>
75. Ruys AT, Tanis PJ, Iris ND, et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. *Ann Surg Oncol* 2011 Jul;18(7):1932-8. <http://www.ncbi.nlm.nih.gov/pubmed/21347794>
76. Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. *Int J Radiat Oncol Biol Phys* 2000 Dec;48(5):1389-93. <http://www.ncbi.nlm.nih.gov/pubmed/11121638>
77. Hunter GK, Balagamwala EH, Koyfman SA, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy (SBRT) for painful spinal metastases from renal cell carcinoma. *International Journal of Radiation Oncology Biology Physics* 2011;81(Suppl 2):S649-S650.
78. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. *Int J Radiat Oncol Biol Phys* 2012 Apr;82(5):1744-8. <http://www.ncbi.nlm.nih.gov/pubmed/21596489>

79. Fokas E, Henzel M, Hamm K, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. *Strahlenther Onkol* 2010 Apr;186(4):210-7..
<http://www.ncbi.nlm.nih.gov/pubmed/20165820>

7. SYSTEMIC THERAPY FOR METASTATIC RCC

7.1 Chemotherapy

Since RCCs develop from the proximal tubules, they have high levels of expression of the multiple-drug resistance protein, P-glycoprotein, and are therefore resistant to most forms of chemotherapy. Chemotherapy appears to be moderately effective only if 5-fluorouracil (5-FU) is combined with immunotherapeutic agents (1). However, in a prospective randomised study, interferon-alpha (IFN- α) showed equivalent efficacy to a combination of IFN- α + interleukin-2 (IL-2) + 5-FU (2).

7.1.1 Conclusion and recommendation

Conclusion	LE
5-FU in combination with immunotherapy is equivalent in efficacy to monotherapy with IFN- α in patients with mRCC.	1b
Recommendation	GR
In patients with clear-cell mRCC, chemotherapy as monotherapy should not be considered effective in patients with mRCC.	B

7.2 Immunotherapy

7.2.1 Interferon alpha as monotherapy and combined with bevacizumab

Interferon alpha has been shown in randomised studies to be superior in relation to survival to hormonal therapy in patients with mRCC (3). IFN- α provided a response rate of 6-15%, together with a 25% decrease in the risk for tumour progression and a modest survival benefit of 3-5 months in comparison with a placebo equivalent (4,5).

The positive effect of IFN- α is particularly apparent in mRCC patients with clear cell histology, good-risk Motzer criteria, and lung metastases only (5). In a prospective randomised study, IFN- α showed equivalent efficacy to a combination of IFN- α + IL2 + 5-FU (2). The moderate efficacy of immunotherapy was also confirmed in a Cochrane meta-analysis including 42 eligible studies (6).

A combination of bevacizumab + IFN- α was recently shown to be associated with increased response rates and better progression-free survival in first-line therapy in comparison with IFN- α monotherapy (7). All recent randomized studies comparing anti-angiogenic drugs in a first-line setting to IFN- α monotherapy have shown superiority for either sunitinib, bevacizumab + IFN- α , or temsirolimus (7-10).

Table 9: Memorial Sloan-Kettering Cancer Center (Motzer) criteria for predicting survival in patients with advanced RCC treated with interferon alpha, depending on the presence or absence of five distinct risk factors (4)

Risk factors*	Cut-off point used
Karnofsky performance status	< 80
Time from diagnosis to treatment with IFN- α	< 12 months
Hemoglobin	< Lower limit of laboratory reference range
Lactate dehydrogenase	> 1.5 times the upper limit of laboratory range
Corrected serum calcium	> 10.0 mg/dL (2.4 mmol/L)

* Favourable (low) risk, no risk factors; intermediate risk, one or two risk factors; poor (high) risk, three or more risk factors.

7.2.2 Interleukin-2

Interleukin-2 (IL-2) has been used to treat mRCC since 1985, with response rates ranging from 7% to 27% (10-12). The optimal IL-2 regimen is not clear, but long-term (> 10 years) complete responses have been achieved

with high-dose bolus IL-2 in a randomised phase III study (13). The toxicity of IL-2 is substantially greater than that of IFN- α . Only clear cell-type RCC responds to immunotherapy. Interleukin-2 has not been validated in controlled randomised studies in comparison with best supportive care (5).

7.2.3 Vaccines and targeted immunotherapy

No recommendations can be made. An earlier phase III trial of vaccine therapy with tumour antigen 5T4 in combination with the first-line standard of care (either sunitinib, interleukin-2, or interferon alpha) failed to demonstrate any survival benefit in comparison with placebo and the first-line standard of care (14). Several phase III vaccination studies are ongoing. Targeted immunotherapy with programmed death-1 ligand (PD-1L), which has shown efficacy and acceptable toxicity in patients with RCC (15), is currently under investigation in a phase II trial in comparison with everolimus in patients in whom anti-angiogenic therapy previously failed.

7.2.4 Conclusions

	LE
Interferon-alpha monotherapy is no longer recommended as first-line therapy for mRCC.	1b
Interferon alpha monotherapy still has a role only in selected cases (good performance status, clear cell type, lung metastases only).	2
Interleukin-2 has more side effects than INF- α .	2-3
High-dose IL-2 is associated with durable complete responses in a limited number of patients.	1b
Interleukin-2 can be considered as monotherapy in selected patients with a good prognosis profile.	1b
A combination of bevacizumab and IFN- α is more effective than IFN- α in treatment-naïve, low-risk and intermediate-risk tumours.	1b
Vaccination therapy with tumour antigen 5T4 showed no survival benefit over the first-line standard of care.	1b

7.2.5 Recommendations

	GR
Monotherapy with IFN- α or high-dose bolus IL-2 can only be recommended as a first-line treatment for mRCC in selected patients with clear cell histology and good prognostic factors.	A
Bevacizumab + IFN- α is recommended as first-line therapy in low-risk and intermediate-risk patients.	B
Only selected patients with mRCC who have a good risk profile and clear cell subtype histology show clinical benefit from immunotherapy with IL-2.	
Cytokine combinations, with or without additional chemotherapy, do not improve the overall survival in comparison with monotherapy.	A

7.3 Drugs targeting VEGF, including other receptor kinases and mammalian target of rapamycin (mTOR)

Recent advances in molecular biology have led to the development of several novel agents for the treatment of mRCC (Table 11).

In sporadic clear cell RCC, hypoxia-inducible factor (HIF) accumulation due to von Hippel-Lindau (VHL) inactivation results in overexpression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both of which promote neoangiogenesis (16-18). This process substantially contributes to the development and progression of RCC. At present, several targeting drugs have been approved both in the USA and in Europe for the treatment of mRCC:

- Sorafenib (Nexavar®)
- Sunitinib (Sutent®)
- Bevacizumab (Avastin®) combined with IFN- α
- Pazopanib (Votrient®)
- Temsirolimus (Torisel®)
- Everolimus (Afinitor®)
- Axitinib (Inlyta®)

New agents targeting angiogenesis are under investigation, as well as combinations of these new agents with each other or with cytokines. One of the new agents targeting angiogenesis, tivozanib, has been investigated in a phase III trial and is currently not approved. Evidence-based data for this drug are presented below. Most published trials have selected for clear cell carcinoma subtypes, and consequently no evidence-based

recommendations can be given for non-clear cell subtypes.

In the major phase III trials leading to registration of the approved targeted agents, patients were stratified according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model, as published in 2002 (3) (Table 9). Since the MSKCC criteria were established in the era of cytokines, an international database consortium has established and validated a risk model (the Database Consortium Model, DCM) which may yield a more accurate prognosis for patients treated in the era of targeted therapy. In the DCM, neutrophilia and thrombocytosis are added to the MSKCC risk factors. By contrast, lactate dehydrogenase (LDH) is omitted from the factors associated with the prognosis (19). The DCM has recently been used to establish data on conditional survival that can be used to counsel patients (20). The DCM has been validated and compared with the risk model of the Cleveland Clinic Foundation (CCF), the French model, MSKCC model, and the International Kidney Cancer Working Group (IKCWG) model. The DCM showed a concordance level of 0.66, which did not differ from the other models, indicating that a ceiling has been reached for clinical risk models for predicting the prognosis based solely on clinical factors. However, the reported versus predicted number of deaths at 2 years was most similar in the DCM in comparison with the other models (21). The DCM has been externally validated for use in the era of targeted therapy (21).

Table 10: Median overall survival and percentage of patients surviving 2 years treated in the era of targeted therapy per DCM risk group, based on the publications by Heng et al. (19,21)

Database Consortium Model ***	Patients**		Median OS* (months)	2-y OS (95% CI) **
	n	%		
Favorable	157	18	43.2	75% (65-82%)
Intermediate	440	52	22.5	53% (46-59%)
Poor	252	30	7.8	7% (2-16%)

* Based on (21); ** based on (19); CI = confidence intervals; OS = overall survival.

7.3.1 Tyrosine kinase inhibitors

7.3.1.1 Sorafenib

Sorafenib is an oral multikinase inhibitor with activity against Raf-1 serine/threonine kinase, B-Raf, vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT-3), and c-KIT. A phase III trial compared sorafenib and placebo after failure of prior systemic immunotherapy or in patients unfit for immunotherapy. The trial reported a 3-month improvement in progression-free survival in favor of sorafenib (22). Survival appears to improve in patients crossed over from placebo to sorafenib treatment (23).

7.3.1.2 Sunitinib

Sunitinib is an oxindol tyrosine kinase (TK) inhibitor. It selectively inhibits PDGFR, VEGFR, c-KIT, and FLT-3 and has antitumour and anti-angiogenic activity. Phase II trials with sunitinib as second-line monotherapy in patients with mRCC demonstrated a partial response in 34-40% of patients and stable disease > 3 months in 27-29% of patients (24).

In a pivotal phase III trial of first-line monotherapy comparing treatment with sunitinib versus IFN- α , sunitinib achieved a longer progression-free survival than IFN- α (11 versus 5 months; $P < 0.000001$). The results suggested that monotherapy with IFN- α was inferior to sunitinib in low-risk and intermediate-risk patients with mRCC (25). The overall survival was 26.4 and 21.8 months in the sunitinib and IFN- α arms, respectively ($P = 0.05$) (25). In patients crossed over from IFN- α to sunitinib ($n = 25$), median survival times were 26.4 versus 20.0 months for sunitinib and IFN- α , respectively ($P = 0.03$). In patients who did not receive any post-study treatment, the median overall survival reached 28.1 months in the sunitinib group versus 14.1 months in the IFN- α group ($P = 0.003$).

In a recent randomised phase II trial including 292 patients, sunitinib 50 mg/day (4 weeks on / 2 weeks off) was compared with a continuous uninterrupted dosage of sunitinib 37.5 mg/day in patients with metastatic clear cell renal carcinoma (26). The median time to progression with sunitinib 50 mg (4/2) ($n = 146$) was 9.9 months, compared with 7.1 months for 37.5 mg/day continuous dosing ($n = 146$). The overall response rate was 32% for 50 mg (4/2) versus 28% for 37.5 mg continuous dosing. No significant differences were observed with regard to overall survival (23.1 vs. 23.5 months; $P = 0.615$), commonly reported adverse events, or patient-reported kidney cancer symptoms. Because of the statistically nonsignificant but numerically longer time to progression with the standard 50 mg (4/2) dosage, the authors recommended adherence to this regimen.

7.3.1.3 Pazopanib

Pazopanib is an oral angiogenesis inhibitor that targets VEGFR, PDGFR, and c-KIT. In a prospective randomized trial of pazopanib versus placebo in treatment-naïve mRCC patients and cytokine-treated patients, there was a significant improvement in the progression-free survival and tumour response (9.2 vs 4.2 months) (27). The trial showed significant results that established pazopanib as a first-line option. Since the initial phase III study involved a substantially smaller number of patients than in phase III studies of other targeted agents, the recommendation was to use pazopanib as second option in first-line treatment. Recently, the results of a randomized phase III non-inferiority trial comparing pazopanib with sunitinib (COMPARZ) showed no significant differences in the outcome parameters, with different toxicity profiles for the two drugs. With a very short follow-up period, these data are not yet mature, particularly with regard to remission. One major shortcoming of the COMPARZ trial is the fact that the study recruited almost one-third of its patients in Asia. Given the fact that there are ethnic differences in side effect profiles, the overall assessment of this trial remains unstable and further interpretation of any subgroups is almost impossible. Full publication is expected, but COMPARZ has established pazopanib as a first-line treatment option.

7.3.1.4 Axitinib

Axitinib is an oral selective second-generation inhibitor of VEGFR-1, -2, and -3 that blocks VEGFR receptors at subnanomolar drug concentrations with minimal inhibition of other targets. It has a short half-life. In the AXIS trial (a randomized phase III trial of axitinib versus sorafenib in patients in whom previous cytokine treatment or targeted agents had failed), the sample size calculation was based on a 40% improvement in the median progression-free survival PFS from 5 months to 7 months in patients randomly assigned to receive axitinib (28). Sorafenib was chosen as the comparator because at the time the trial was designed there was no standard for second-line treatment after failure of a previous VEGF targeted therapy. With 723 patients included, the overall median progression-free survival was 6.7 months for patients in the axitinib group in comparison with 4.7 months for those in the sorafenib group (hazard ratio [HR] 0.67; 95% CI, 0.54 to 0.81). However, the difference in PFS was greatest in the patients in whom cytokine treatment had failed. For those in whom sunitinib had failed ($n = 194$ axitinib and $n = 195$ sorafenib), axitinib led to a PFS of 4.8 months (95% CI, 4.5 to 6.4) versus 3.4 months (95% CI, 2.6 to 4.7) for sorafenib.

In the AXIS trial, axitinib showed greater than or equal to grade 3 toxicity for diarrhea in 11%, hypertension in 16%, and fatigue in 11%. Across all grades, nausea was recorded in 32%, vomiting in 24%, and asthenia in 21%. Overall survival (OS) was a secondary end point of the trial, but these data were not mature at the time of publication. However, since crossover was not allowed in this trial comparing two active VEGFR inhibitors, the data have in the meantime been analyzed and showed no significant differences between axitinib and sorafenib in second-line treatment (29).

7.3.1.5 Tivozanib

Tivozanib is an oral selective tyrosine kinase inhibitor targeting all three VEGF receptors. It has a long half-life. Tivozanib showed activity and tolerability in a phase II discontinuation trial. The overall response rate was 24% (95% CI, 19% to 30%), and the median PFS was 11.7 months (95% CI, 8.3 to 14.3 months) in the trial population. The most common grade 3 and 4 treatment-related adverse event was hypertension (12%) (30). The results of a phase III trial of tivozanib versus sorafenib in treatment-naïve mRCC patients or those having received one prior systemic treatment excluding VEGF targeted therapy or mTOR inhibitors were reported at the American Society of Clinical Oncology (ASCO) meeting in 2012, and full publication is pending. For the 70% treatment-naïve patients enrolled, the median PFS was 12.7 months for tivozanib versus 9.1 months for sorafenib (HR 0.756; 95% CI, 0.580 to 0.985). For all patients, the objective response rates were 33% for tivozanib versus 23% for sorafenib. The most common adverse events (AEs) for tivozanib (all grades / \geq grade 3) were hypertension (46%/26%), diarrhea (22%/2%), fatigue (18%/5%), and neutropenia (10%/2%) (31). Full publication of this study is pending. If approved, tivozanib might be a tyrosine kinase inhibitor with effectiveness not inferior to that of sorafenib, as apparent in the groups of patients tested.

7.3.2 Monoclonal antibody against circulating VEGF

7.3.2.1 Bevacizumab monotherapy and combined with interferon alpha

Bevacizumab is a humanized monoclonal antibody that binds isoforms of VEGF-A. Bevacizumab 10 mg/kg every 2 weeks in patients refractory to immunotherapy was associated with an increase in the overall response (10%) and in the progression-free survival in comparison with placebo (27). A double-blind phase III trial (AVOREN) ($n = 649$) in patients with mRCC compared bevacizumab + IFN- α with IFN- α monotherapy (7). The median overall response was 31% in the bevacizumab + IFN- α group versus 13% in the group receiving only IFN- α ($P < 0.0001$). The median progression-free survival increased significantly from 5.4 months with IFN- α to 10.2 months with bevacizumab + IFN- α ($P < 0.0001$), but only in low-risk and intermediate-risk patients. No benefit was seen in high-risk patients. In a recent update, the median OS in the AVOREN trial, which allowed

crossover after progression, was 23.3 months for bevacizumab-IFN- α versus 21.3 months for IFN- α alone ($P < 0.336$) (32).

A similarly designed trial (CALGB 90206), including 732 patients (33,34), of bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN (9 million units subcutaneously three times weekly) versus IFN (9 million units subcutaneously three times weekly) showed a median PFS of 8.5 months for the combination versus 5.2 months for IFN- α alone. The median OS with a crossover design was 18.3 months for the combination versus 17.4 months for IFN- α alone. Bevacizumab plus IFN- α had a higher objective response rate (ORR) in comparison with IFN (25.5%: 95% CI, 20.9% to 30.6%; vs. 13.1%: 95% CI, 9.5% to 17.3%); $P < 0.0001$). The overall toxicity was greater for bevacizumab plus IFN- α , with significantly more grade 3 hypertension (9% vs. 0%), anorexia (17% vs. 8%), fatigue (35% vs. 28%), and proteinuria (13% vs. 0%).

7.3.3 Mammalian target of rapamycin (mTOR) inhibitors

7.3.3.1 Temsirolimus

Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) (35). Patients with high-risk mRCC were randomly assigned in a phase III trial (NCT00065468) to receive first-line treatment with temsirolimus or IFN- α monotherapy, or a combination. In the temsirolimus group, the overall survival was 10.9 months versus 7.3 months in the IFN- α group ($P < 0.0069$). However, the overall survival in the temsirolimus + IFN- α group was not significantly improved (9).

7.3.3.2 Everolimus

Everolimus is an oral mTOR inhibitor. A phase III study (RECORD-1) compared everolimus plus best supportive care (BSC) versus placebo plus BSC in patients in whom previous anti-VEGFR treatment had failed. The median progression-free survival was 4 months with everolimus versus 1.9 months with placebo ($P < 0.001$). In the RECORD-1 trial, 124 patients (46%) had received sunitinib as the only previous systemic treatment, with a PFS of 4.0 months (95% CI, 3.7 to 5.5 months). Comparison with the AXIS data is complicated by the fact that in the RECORD-1 trial, 53% of the patients with progression after previous targeted therapy had at least more than one previous treatment, often cytokines prior to tyrosine kinase inhibitors (TKIs). In addition, the PFS analysis in this trial was not specifically carried out for previous sunitinib treatment (16,36).

7.3.4 Sequencing targeted therapy

Currently, no recommendations can be given as to the best sequence of targeted therapy. The AXIS trial is the only recent randomized phase III superiority trial comparing two TKIs after failure of a prior TKI. The results and interpretation are described under 7.3.1.3 above. For the subgroup of patients treated previously with sunitinib, the difference in PFS did not reach statistical significance for axitinib versus sorafenib, and no difference in the OS was observed. Randomized phase III trials investigating the safety and efficacy of sorafenib followed by sunitinib versus sunitinib followed by sorafenib (SWITCH-I) and sequential pazopanib and sorafenib versus sorafenib and pazopanib (SWITCH-II) are ongoing.

7.3.5 Combination of targeted agents

No recommendations can be made. At present, there have been no phase III trials reporting on a combination of two targeted agents versus monotherapy with a targeted agent. A previous randomised phase II study reported unacceptable toxicity (37). The TORAVA trial showed that the toxicity of a combination of temsirolimus and bevacizumab was much greater than anticipated and that it limited treatment continuation over time in comparison with either standard treatment with sunitinib or bevacizumab and IFN- α . In addition, clinical activity was low in comparison with the benefit expected from sequential use of each targeted therapy. This combination has not been further recommended or investigated. In a nonrandomized phase II trial, the combination of everolimus with bevacizumab was found to be effective with acceptable toxicity, except for grade 3/4 proteinuria in 25% of the patients (38). A randomised phase II trial of everolimus in combination with bevacizumab and IFN- α versus IFN- α alone is ongoing.

7.3.6 Non-clear cell renal cancer

No recommendations can be made at present. No phase III trials on systemic treatment of patients with non-clear cell carcinoma have been reported. A nonrandomized phase II trial in patients with papillary renal cancer who were treated with foretinib, a dual MET/VEGFR2 inhibitor, reported activity and acceptable toxicity with high response rates in patients with germline MET mutations (39). Patients should be treated in the framework of clinical trials. If a trial is not available, a decision can be made in consultation with the patient to perform treatment in line with clear cell renal cell carcinoma.

Table 11: European Association of Urology 2013 evidence-based recommendations for first-line and second-line systemic therapy in patients with mRCC. Levels of evidence are shown in square brackets

RCC type	MSKCC risk group (3)	1st-line therapy*	2nd-line therapy*†	3rd-line therapy
Clear cell	Favorable or intermediate	<ul style="list-style-type: none"> • Sunitinib [1b] • IFN-α + bevacizumab [1b] Pazopanib ‡ [1b] 	<i>After prior TKI:</i> <ul style="list-style-type: none"> • Axitinib [1b] • Sorafenib [1b] • Everolimus [1b] 	<ul style="list-style-type: none"> • Everolimus after prior TKI(s) [1b]
		<i>In selected patients:</i> <ul style="list-style-type: none"> • IFN-α [1b] • High-dose IL-2 [1b] 	<i>After prior cytokines:</i> <ul style="list-style-type: none"> • Sorafenib [1b] • Axitinib [1b] • Pazopanib [1b] 	
	Poor ¶	<ul style="list-style-type: none"> • Temsirolimus [1b] 		
Non-clear cell	Favorable	§		
	Intermediate	§		
	Poor	§		

IFN- α = interferon alpha; MSKCC = Memorial Sloan-Kettering Cancer Center; RCC = renal cell carcinoma; TKI = tyrosine kinase inhibitor.

* Doses: IFN- α 9 MU three times per week subcutaneously, bevacizumab 10 mg/kg biweekly intravenously; sunitinib 50 mg daily orally for a period of 4 weeks, followed by 2 weeks of rest (37.5 mg continuous dosing did not show significant differences); temsirolimus 25 mg weekly intravenously; pazopanib 800 mg daily orally. Axitinib 5 mg twice daily, to be increased to 7 mg twice daily, unless greater than grade 2 toxicity, blood pressure higher than 150/90 mmHg, or the patient is receiving antihypertensive medication.

† Listed in the order of data quality.

‡ Initial phase III study; involved a substantially smaller number of patients than in phase III studies of other targeted agents.

§ No standard treatment available. Patients should be treated in the framework of clinical trials. If a trial is not available, a decision can be made in consultation with the patient to perform treatment in line with clear cell renal cell carcinoma.

¶ Poor risk criteria in the NCT00065468 trial consisted of MSKCC (3) risk plus metastases in multiple organs.

7.3.7 Conclusions

	LE
Tyrosine kinase inhibitors (TKIs) increase the progression-free survival and/or overall survival as both first-line and second-line treatments for mRCC.	1b
Sorafenib has proven efficacy as a second-line treatment after failure of cytokine therapy or in patients unfit for cytokines.	1b
Axitinib has proven efficacy and superiority as a second-line treatment after failure of cytokines and VEGF-targeted therapy in comparison with sorafenib.	1b
Sunitinib is more effective than IFN- α in treatment-naïve low-risk and intermediate-risk tumours.	1b
Sunitinib at 50 mg (4/2) or 37.5 mg continuous dosing did not show significant differences in relation to overall survival, time to progression, response rate, or safety.	1b
A combination of bevacizumab and IFN- α is more effective than IFN- α in treatment-naïve low-risk and intermediate-risk tumours.	1b
Pazopanib is superior to placebo in both naïve mRCC patients and post-cytokine patients.	1b
Pazopanib is not inferior to sunitinib in good-risk and intermediate-risk clear cell mRCC patients.	1b
Temsirolimus monotherapy in poor-risk mRCC patients is more effective than IFN- α or temsirolimus + IFN- α .	1b
Everolimus prolongs the progression-free survival in patients in whom treatment with one or two TKIs has failed in second-line or later treatments.	1b

The role of the new drugs is still under development and combination studies are ongoing. To date, no data are available indicating whether the new agents have a curative effect. These agents appear promising for stabilizing mRCC for a prolonged period of time. However, this promise has to be balanced against their toxicity profile and the patient's quality of life. Anti-angiogenic monotherapy and its sequences have become the standard of care in mRCC treatment.	4
--	---

7.3.7 Recommendations for systemic therapy for mRCC

Recommendations	GR
Sunitinib is recommended as first-line therapy in favorable-risk and intermediate-risk patients.	A
Bevacizumab + IFN- α is recommended as first-line therapy in favourable-risk and intermediate-risk patients.	A
Sorafenib is recommended as a second-line treatment for mRCC after cytokine failure.	A
Pazopanib is recommended as first-line or after cytokine failure in favourable-risk and intermediate-risk patients.	A
Temsirolimus is recommended as first-line treatment in poor-risk patients.	A
Everolimus is recommended as second-line treatment after failure of tyrosine kinase inhibitors.	A
Axitinib is recommended as second-line treatment after failure of cytokines or tyrosine kinase inhibitors.	A

7.4 References

1. Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. *J Urol* 2003 Oct;170(4 Pt 1):1141-5. <http://www.ncbi.nlm.nih.gov/pubmed/14501711>
2. Gore ME, Griffin CL, Hancock B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. *Lancet* 2010 Feb 20;375(9715):641-8. <http://www.ncbi.nlm.nih.gov/pubmed/20153039>
3. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. *Medical Research Council Renal Cancer Collaborators. Lancet* 1999 Jan;353(9146):14-7. <http://www.ncbi.nlm.nih.gov/pubmed/10023944>
4. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002 Jan;20(1):289-96. <http://www.ncbi.nlm.nih.gov/pubmed/11773181>
5. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. *Cochrane Database Syst Rev* 2005 Jan;(1):CD001425. <http://www.ncbi.nlm.nih.gov/pubmed/15674877>
6. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. *Cochrane Database Syst Rev* 2005 Jan 25;(1):CD001425. <http://www.ncbi.nlm.nih.gov/pubmed/15674877>
7. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* 2007 Dec;370(9605):2103-11. <http://www.ncbi.nlm.nih.gov/pubmed/18156031>
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007 Jan;356(2):115-24. <http://www.ncbi.nlm.nih.gov/pubmed/17215529>
9. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007 May;356(22):2271-81. <http://www.ncbi.nlm.nih.gov/pubmed/17538086>
10. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 1993 Apr;21(85):622-32. <http://www.ncbi.nlm.nih.gov/pubmed/8468720>
11. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1995 Mar;13(3):688-96. <http://www.ncbi.nlm.nih.gov/pubmed/7884429>

12. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2005 Jan;23(1):133-41.
<http://www.ncbi.nlm.nih.gov/pubmed/15625368>
13. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol* 2003 Aug;21(16):3127-32.
<http://www.ncbi.nlm.nih.gov/pubmed/12915604>
14. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. *Clin Cancer Res* 2010 Nov;16(22):5539-47.
<http://www.ncbi.nlm.nih.gov/pubmed/20881001>
15. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012 Jun 28;366(26):2455-65.
<http://www.ncbi.nlm.nih.gov/pubmed/22658128>
16. Patel PH, Chadalavada RS, Chaganti RS, et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. *Clin Cancer Res* 2006 Dec;12(24):7215-20.
<http://www.ncbi.nlm.nih.gov/pubmed/17189392>
17. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003 Jul;349(5):427-34.
<http://www.ncbi.nlm.nih.gov/pubmed/12890841>
18. Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. *Eur Urol* 2006 Apr;49(4):633-43.
<http://www.ncbi.nlm.nih.gov/pubmed/16481093>
19. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol* 2009 Dec;27(34):5794-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19826129>
20. Harshman LC, Xie W, Bjarnason GA, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. *Lancet Oncol* 2012 Sep;13(9):927-35.
<http://www.ncbi.nlm.nih.gov/pubmed/22877847>
21. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol* 2013 Feb;14(2):141-8.
<http://www.ncbi.nlm.nih.gov/pubmed/23312463>
22. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. *N Engl J Med* 2007 Jan;356(2):125-34.
<http://www.ncbi.nlm.nih.gov/pubmed/17215530>
23. Bellmunt J, Négrier S, Escudier B, et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. *Crit Rev Oncol Hematol* 2009 Jan;69(1):64-72.
<http://www.ncbi.nlm.nih.gov/pubmed/18774306>
24. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2006 Jan;24(1):16-24.
<http://www.ncbi.nlm.nih.gov/pubmed/16330672>
25. Figlin RA, Hutson TE, Tomczac P, et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. *ASCO Annual Meeting Proceedings* 2008. *J Clin Oncol* 2008;26(Suppl.):Abstr 5024.
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32895
26. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. *J Clin Oncol* 2012 Apr 20;30(12):1371-7.
<http://www.ncbi.nlm.nih.gov/pubmed/22430274>
27. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. *J Clin Oncol*. 2010 Feb 20;28(6):1061-8.
<http://www.ncbi.nlm.nih.gov/pubmed/20100962>

28. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet* 2011 Dec 3;378(9807): 1931-9.
<http://www.ncbi.nlm.nih.gov/pubmed/22056247>
29. Dror Michaelson M, Rini BI, Escudier BJ, et al. Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients. *J Clin Oncol* 30, 2012 (suppl; abstr 4546).
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94426
30. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. *J Clin Oncol* 2012 May 10;30(14):1678-85.
<http://www.ncbi.nlm.nih.gov/pubmed/22493422>
31. Motzer R, Nosov D, Eisen T, et al (2012). Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. *J Clin Oncol* 30: abstr 4501.
http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=96560
32. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. *J Clin Oncol* 2010 May 1;28(13):2144-50.
<http://www.ncbi.nlm.nih.gov/pubmed/20368553>
33. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 2008 Nov 20;26(33):5422-8.
<http://www.ncbi.nlm.nih.gov/pubmed/18936475>
34. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. *J Clin Oncol* 2010 May 1;28(13):2137-43.
<http://www.ncbi.nlm.nih.gov/pubmed/20368558>
35. Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. *Crit Rev Oncol Hematol* 2006 Dec;60(3):216-26.
<http://www.ncbi.nlm.nih.gov/pubmed/16860997>
36. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. *Lancet* 2008 Aug;372(9637):449-56.
<http://www.ncbi.nlm.nih.gov/pubmed/18653228>
37. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. *Lancet Oncol* 2011 Jul;12(7):673-80.
<http://www.ncbi.nlm.nih.gov/pubmed/21664867>
38. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. *J Clin Oncol* 2010 May 1;28(13):2131-6.
<http://www.ncbi.nlm.nih.gov/pubmed/20368560>
39. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. *J Clin Oncol* 2013 Jan 10;31(2):181-6.
<http://www.ncbi.nlm.nih.gov/pubmed/23213094>

8. FOLLOW-UP AFTER RADICAL OR PARTIAL NEPHRECTOMY OR ABLATIVE THERAPIES FOR RCC

8.1 Introduction

Surveillance after treatment for renal cell carcinoma (RCC) allows the urologist to monitor or identify:

- Postoperative complications
- Renal function
- Local recurrence after partial nephrectomy or ablative treatment
- Recurrence in the contralateral or ipsilateral (after partial nephrectomy) kidney
- Development of metastases

The method and timing of examinations have been the subject of many publications. There is no consensus on surveillance after treatment for RCC, and in fact there is no evidence that early versus later diagnosis of recurrences improves survival. However, follow-up is important in order to increase the information about RCC available, and it should be performed by the urologist, who should record the time that has elapsed up to a recurrence or the development of metastases.

Postoperative complications and renal function are readily assessed by the patient's history, physical examination, and measurement of serum creatinine and estimated glomerular filtration rate (eGFR). Repeated long-term monitoring of eGFR is indicated if there is impaired renal function before surgery, or postoperative deterioration. Renal function (1,2) and non-cancer survival (3-5) can be optimized by carrying out nephron-sparing surgery whenever possible for T1 and T2 tumours (6) (LE: 3). Tumour-bed recurrence is rare (2.9%), but early diagnosis is useful, since the most effective treatment is cytoreductive surgery (7,8). Recurrence in the contralateral kidney is also rare (1.2%) and is related to positive margins, multifocality, and grade (9) (LE: 3).

The reason for carrying out surveillance is to identify local recurrences or metastases at an early stage. This is particularly important with ablative therapies such as cryotherapy and radiofrequency ablation (RFA). Although the local recurrence rate is higher than after conventional surgery, the patient may still be cured using repeat ablative therapy or radical nephrectomy (10) (LE: 3). In metastatic disease, more extended tumour growth can limit the opportunity for surgical resection, which is considered the standard therapy in cases of resectable and preferably solitary lesions. In addition, in clinical trials, an early diagnosis of tumour recurrence may enhance the efficacy of a systemic treatment if the tumour burden is low.

8.2 Which investigations for which patients, and when?

Intensive radiological surveillance for all patients is unnecessary. For example, the outcome after surgery for T1a low-grade tumours is almost always excellent. It is therefore reasonable to stratify the follow-up, taking into account the risk of a recurrence or metastases developing. Although there is no randomized evidence, there have been large studies examining prognostic factors with long follow-up periods, from which some conclusions can be drawn (11-13) (LE: 4):

- The sensitivity of chest radiography for small metastases is poor and ultrasound has limitations. Surveillance should therefore not be based on these imaging modalities. With low-risk tumours, the surveillance intervals should be adapted relative to radiation exposure and benefit. Magnetic resonance imaging (MRI) can be used to reduce radiation exposure.
- When the risk of relapse is intermediate or high, computed tomography (CT) of the chest and abdomen is the investigation of choice, although the significant morbidity associated with the radiation exposure involved in repeated CT scans should be taken into account (14).
- Surveillance should also include clinical evaluation of renal function and cardiovascular risk factors.
- Positron-emission tomography (PET) and PET-CT as well as bone scintigraphy are not the standard of care in RCC surveillance, due to their limited specificity and sensitivity.

Depending on the availability of effective new treatments, more strict follow-up schedules may be required, particularly as there is a higher local recurrence rate after cryotherapy and RFA. There is controversy over the optimal duration of follow-up. Some argue that follow-up with imaging is not cost-effective after 5 years; however, late metastases are more likely to be solitary and justify more aggressive therapy with curative intent. In addition, patients with tumours that develop in the contralateral kidney can be treated with nephron-sparing surgery if the tumours are detected when small. In addition, for tumours < 4 cm in size, there is no difference between partial and radical nephrectomy with regard to recurrences during the follow-up (15) (LE: 3).

Several authors - notably Kattan, Liebovich, UCLA, and Karakiewicz (16-19) - have designed scoring systems and nomograms to quantify the likelihood of patients developing tumour recurrences, metastases, and subsequent death. These systems have been compared and validated (20) (LE: 2). Using prognostic variables,

several stage-based surveillance regimens have been proposed (21,22), but these do not include ablative therapies. A postoperative nomogram is available for estimating the likelihood of freedom from recurrence at 5 years (23). Most recently, a preoperative prognostic model based on age, symptoms, and TNM staging has been published and validated (24) (LE: 3). There is therefore a need for a surveillance algorithm for monitoring patients after treatment for RCC, recognizing not only the patient risk profile, but also the efficacy of the treatment given (Table 11).

Table 12: Proposed algorithm for surveillance following treatment for RCC, taking into account patient risk profile and treatment efficacy

Risk profile	Treatment	Surveillance						
		6 mo	1 y	2 y	3 y	4 y	5 yr	> 5 y
Low	RN/PN only	US	CT	US	CT	US	CT	Discharge
Intermediate	RN/PN/ cryo/RFA	CT	US	CT	US	CT	CT	CT once every 2 years
	High	RN/PN/ cryo/RFA	CT	CT	CT	CT	CT	CT once every 2 years

Cryo = cryotherapy; CT = computed tomography of chest and abdomen, or MRI = magnetic resonance imaging; PN = partial nephrectomy; RFA = radiofrequency ablation; RN = radical nephrectomy; US = ultrasound of abdomen, kidneys and renal bed.

8.3 Conclusions and recommendations for surveillance following radical or partial nephrectomy or ablative therapies for RCC

Conclusion
The aim of surveillance is to detect either local recurrence or metastatic disease while the patient is still surgically curable.

Recommendations	LE	GR
Surveillance after treatment for RCC should be based on a patient's risk factors and the type of treatment delivered.		C
For low-risk disease, CT/MRI can be used infrequently.	4	C
In the intermediate-risk group, intensified follow-up should be performed, including CT/MRI scans at regular intervals in accordance with a risk-stratified nomogram.	4	C
In high-risk patients, the follow-up examinations should include routine CT/MRI scans.	4	C
There is an increased risk of intrarenal recurrences in larger-size (> 7 cm) tumours treated with nephron-sparing surgery, or when there is a positive margin. Follow-up should be intensified in these patients.		C

8.4 References

- Pettus JA, Jang TL, Thompson RH, et al. Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors. *Mayo Clin Proc* 2008 Oct;83(10):1101-6.
<http://www.ncbi.nlm.nih.gov/pubmed/18828969>
- Snow DC, Bhayani SB. Chronic renal insufficiency after laparoscopic partial nephrectomy and radical nephrectomy for pathologic T1A lesions. *J Endourol* 2008 Feb;22(2):337-41.
<http://www.ncbi.nlm.nih.gov/pubmed/18257672>
- Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared to partial nephrectomy. *J Urol* 2008 Feb;179(2):468-71; discussion 472-3.
<http://www.ncbi.nlm.nih.gov/pubmed/18076931>
- Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? *J Urol* 2009 Jan;181(1):55-61; discussion 61-2.
<http://www.ncbi.nlm.nih.gov/pubmed/19012918>

5. Zini L, Perotte P, Capitanio U, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer* 2009 Apr;115(7):1465-71.
<http://www.ncbi.nlm.nih.gov/pubmed/19195042>
6. Jeldres C, Patard JJ, Capitano U, et al. Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics. *Urology* 2009 Jun;73(6):1300-5.
<http://www.ncbi.nlm.nih.gov/pubmed/19376568>
7. Bruno JJ, Snyder ME, Motzer RJ, et al. Renal cell carcinoma local recurrences, impact of surgical treatment and concomitant metastasis on survival. *BJU Int* 2006 May;97(5):933-8.
<http://www.ncbi.nlm.nih.gov/pubmed/16643473>
8. Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. *BJU Int* 2005 Mar;95(4):522-5.
<http://www.ncbi.nlm.nih.gov/pubmed/15705072>
9. Bani-Hani AH, Leibovich BC, Lohse CM, et al. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. *J Urol* 2005 Feb;173(2):391-4.
<http://www.ncbi.nlm.nih.gov/pubmed/15643178>
10. Matin SF, Ahrar K, Cadeddu JA, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. *J Urol* 2006 Nov;176(5):1973-7.
<http://www.ncbi.nlm.nih.gov/pubmed/17070224>
11. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *J Urol* 2005 Jun;173(6):1853-62.
<http://www.ncbi.nlm.nih.gov/pubmed/15879764>
12. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int* 2009 Jun;103(11):1496-500.
<http://www.ncbi.nlm.nih.gov/pubmed/19076149>
13. Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. *J Urol* 2009 Feb;181(2) 506-11.
<http://www.ncbi.nlm.nih.gov/pubmed/19084868>
14. Ionising Radiation (Medical Exposures) Regulations 2000. National Radiation Protection Board 2000.
<http://www.legislation.gov.uk/uksi/2000/1059/contents/made>
15. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. *J Urol* 2004 Jun;171(6 Pt 1):2181-5; quiz 2435. <http://www.ncbi.nlm.nih.gov/pubmed/15126781>
16. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001 Jul;166(1):63-7.
<http://www.ncbi.nlm.nih.gov/pubmed/11435824>
17. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognosticated nomogram and risk group stratification system. *J Urol* 2005 Aug;174(2):466-72; discussion 472; quiz 801.
<http://www.ncbi.nlm.nih.gov/pubmed/16006866>
18. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer* 2003 Apr;97(7):1663-71.
<http://www.ncbi.nlm.nih.gov/pubmed/12655523>
19. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. *J Clin Oncol* 2007 Apr;25(11):1316-22.
<http://www.ncbi.nlm.nih.gov/pubmed/17416852>
20. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. *Cancer* 2005 Oct;104(7):1362-71.
<http://www.ncbi.nlm.nih.gov/pubmed/16116599>
21. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. *Eur Urol* 2007 Jun;51(6):1490-500; discussion 1501.
<http://www.ncbi.nlm.nih.gov/pubmed/17229521>
22. Chin AI, Lam JS, Figlin RA, et al. Surveillance strategies for renal cell carcinoma patients following nephrectomy. *Rev Urol* 2006 Winter;8(1):1-7.
<http://www.ncbi.nlm.nih.gov/pubmed/16985554>

23. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol* 2005 Jan;173(1):48-51.
<http://www.ncbi.nlm.nih.gov/pubmed/15592023>
24. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. *Eur Urol* 2009 Feb;55(2):287-95.
<http://www.ncbi.nlm.nih.gov/pubmed/18715700>

9. ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations

ACKD	acquired cystic kidney disease
AML	Angiomyolipoma
5FU	5-fluorouracil
BSC	best supportive care
CaIX	carbonic anhydrase IX
cRCC	clear cell renal carcinoma
chRCC	chromophobe renal cell carcinoma
CT	computed tomography
ESKD	end-stage kidney disease
FLT-3	FMS-like tyrosine kinase 3
GR	grade of recommendation
HIF	hypoxia inducible factor
HIFU	high-intensity focused ultrasound
HU	Hounsfield unit
IFN-alpha	interferon-alpha
IL-2	interleukin-2
LE	level of evidence
MESTK	mixed epithelial and stromal tumour of the kidney
mRCC	metastatic renal cell carcinoma
MRI	magnetic resonance imaging
mTOR	mammalian target of rapamycin
NSS	nephron-sparing surgery
PA	predictive accuracy
pRCC	papillary renal cell carcinoma
RCC	renal cell carcinoma
PDGF	platelet-derived growth factor
PDGFR	platelet-derived growth factor receptor
PET	positron emission tomography
PTEN	phosphatase and tensin homolog
REST	Renal epithelial and stromal tumours
RF	radiofrequency
RFA	radiofrequency ablation
SAE	selective arterial embolisation
TFE3	transcription factor E3
TK	tyrosine kinase
TKI	Tyrosine kinase inhibitors
TNM	Tumour Node Metastasis
US	abdominal ultrasound
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
VHL	von Hippel-Lindau
WHO	World Health Organization

Conflict of interest

All members of the Renal Cell Cancer working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.